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CHAPTER 1: INTRODUCTION AND BACKGROUND
Ovarian cancer
Ovarian cancer represents the malignant transformation of the female gonad. There are
three main types of ovarian cancer: epithelial, which comprises the majority, germ cell, and sex
cord-stromal, representing less than 2% of the cases. The histopathologic classification of
epithelial ovarian cancer (EOC) includes serous, endometrioid, clear-cell, and mucinous.
Genomic studies of high-grade serous cancer have identified molecular subtypes that are
associated with distinct biology and clinical outcome. Recent evidence suggests two different
entities based on molecular signatures: type-1 and type-2 EOC. Type-1 is slow-growing and has
a “cure” rate of about 90% as compared to the more aggressive type-2, which encompasses the
majority of cases [1]. Type-2 EOC typically expresses mutations in tumor-suppressor and/or
DNA repair genes [1]. Regardless of molecular subtype, mortality from EOC is high in patients
with advanced-stage and high-grade serous EOCs. Although the exact etiology of EOC in the
general population remains elusive, BRCA1/2-mutation carriers and those affected with Lynch II
syndrome are considered to be high risk [2, 3]. Indeed, a strong family history of EOC is the
single most important risk factor [2, 4].

Nulliparity is another risk factor; however, oral

contraceptive use, tubal ligation, pregnancy, and lactation confer protection against the disease
[4-6].

Evidence suggests that factors involved in cell pluripotency and self-renewal, key

characteristics of stem cells, are implicated in cancer biology [7-19]. Specifically, the existence
of human ovarian cancer-initiating cells (OCICs) with stemness properties and enhanced
resistance to cisplatin and paclitaxel have been reported [13]. Among different proposed theories
for the pathogenesis of EOC, the “incessant ovulation” model is the most widely accepted [20].
Accordingly, cyclical ovulations without intervening pregnancy will, overtime, increase the
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likelihood of chronic inflammation and generation of reactive oxygen and nitrogen species (ROS
and RNS) that may induce various mutations, and concomitant with impairment of repair
mechanisms will initiate tumorigenesis [21-23]. Typically, the treatment of ovarian cancer
requires both cytoreductive surgery (CRS) and platinum/taxane combination chemotherapy [2427].

Recently, targeted agents such as anti-angiogenic drugs have been introduced in the

management of ovarian cancer patients.
Epithelial ovarian cancer is the deadliest of all gynecologic cancers with an estimated
22,280 new cases and 14,240 deaths expected in 2016 in the US alone [28]. The 5-year survival
rate for localized ovarian cancer is approximately 90%, but drops dramatically to 60% for
regional disease and 20% for metastatic disease. Because early-stage ovarian cancer presents
with nonspecific symptoms, frequently the diagnosis is not made until after the malignancy has
spread beyond the ovaries [29]. The high mortality rates for this type of malignancy can be
largely attributed to a lack of screening methods for the general population and the acquisition of
resistance to the current chemotherapeutics [29].
Cisplatin resistance
Resistance to chemotherapy can be either intrinsic, occurring at the onset of treatment, or
acquired, when the disease recurs despite an initially successful response [30-32]. Generally, the
approach to relapsed disease is stratified based upon the amount of time that has elapsed between
the completion of platinum-based treatment and the detection of relapse, established as the
platinum-free interval (PFI) [33]. Patients with a PFI of less than six months are considered
platinum-resistant as opposed to those with a PFI greater than the six-month cutoff.
Approximately 75% of patients with advanced disease will respond initially to platinumcontaining chemotherapy. However the majority will relapse within two years of completing
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treatment, while 25% of patients are intrinsically resistant [30, 34, 35]. Chemoresistance greatly
limits the range of possibilities for subsequent treatments, because some tumors become resistant
not only to the initial drug but also to new therapeutic agents with different mechanisms of action
[31]. Attempts to overcome drug resistance are central to both clinical and basic molecular
research in cancer chemotherapy [30].
Cisplatin,the prototype of the platinum drugs, is well characterized with a long track
record in both basic science and clinical research. Carboplatin, a platinum compound, has
replaced cisplatin in the treatment of EOC because of its superior toxicity profile. The
mechanisms of action of cisplatin involve both cytoplasmic and nuclear reactions [23, 36-39].
After being actively transported to the intracellular compartment by the copper transporters
(CTR1), the cisplatin molecule becomes activated by a series of aquation reactions that consist of
the substitution of one or both cis-chloro groups with water
molecules (Figure 1) [40-42]. Cisplatin avidly binds DNA,
with a predilection for nucleophilic N7-sites on purine
bases.

This leads to the generation of protein–DNA

Figure 1. Molecular structure
complexes as well as of DNA–DNA inter- and intra-strand of cisplatin.
adducts, with the latter being more lethal. Generally p53 will be activated following DNA
damage. This will lead to cell cycle arrest for DNA repair, or activation of the apoptosis
pathway with cytochome c release. Of note, it is possible that mutations occur during the DNA
repair process.

Additionally, cisplatin is known to generate ROS by the activation of

nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase in the cell membrane and the
mitochondria[43-45].

The glutathione/glutathione disulfide (GSH/GSSG) pathway is very

important to scavenge ROS and activate drug efflux pumps, which can expel cisplatin from the
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cell.

The imbalance between the production and elimination of free radicals and reactive

metabolites leads to a state of oxidative stress and subsequent damage of important biomolecules
and cells, with potential impact on the whole organism [46].
Several possible mechanisms of cisplatin resistance have been previously described;
including decreased intracellular aquation, decreased uptake and accelerated efflux due to
increased activity of ATP-binding cassette and soluble carrier transporter families[47, 48]. Here,
we have classified those mechanisms as follow: 1) pharmacokinetic (PK) variations, 2)
activation of DNA repair, 3) decrease cell death such as apoptosis and autophagy, and alterations
of cell signaling pathways, 4) cancer stem cells, 5) tumor microenvironment and, 6) oxidative
stress.
1) Pharmacokinetic variations
Pharmacokinetics is a branch or pharmacology that describes how the body affects a
specific drug after administration through the mechanisms of absorption, distribution,
metabolism, and the elimination of the drug [49]. The PK properties of drugs may be affected by
elements such as the site of administration, the absorptive surface, the volume of distribution,
and more importantly the genetic makeup and morphometric characteristics of the individual
receiving the specified drug [50, 51]. Genetic variations in expression and polymorphisms of
enzymes that are involved in some of these processes have been identified, and are in part
responsible for some of the inter-patient variations of drug effects. Similarly, the morphometric
parameters such as height, weight and overall body composition; as well as disease status and
environmental factors may play important roles.
Several studies have demonstrated the role of copper transporters to decreased tumor
response to platinum compounds [52-56]. Clinically relevant concentrations of cisplatin were
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shown to downregulate the CTR1, by internalization followed by proteasome-mediated
degradation [57-59]. Additionally, the Wilson disease protein, also known as ATP7B, is a Ptype cation transport ATPase that functions as a monomer, exporting copper out of the cells was
reported to correlate with cisplatin resistance in preclinical studies[60-62]. However when
studied in patients, its expression level was not significantly correlated with the known multidrug resistant markers (MDRs), but found to be an independent prognosticator [63, 64].
Additional studies in both ovarian and endometrial cancers further validate ATP7B as predictive
marker of chemoresistance for cisplatin [63-65].
Once inside of the cell, cisplatin becomes activated through an aquation reaction. This
reaction occurs spontaneously in the cytoplasm, owing to the relatively low concentration of
chloride ions (2–10 mM) when compared with the extracellular milieu (100 mM), and leads to
the generation of highly reactive mono-and biaquated cisplatin forms. Cisplatin avidly binds to
cytoplasmic nucleophilic species, including GSH, methionine, metallothioneins and other
cysteine-rich proteins, and is then sequestered.

As a result, the effective intracellular

concentration of cisplatin is diminished leading to the development of chemoresistance.
Voltage-dependent anion channels (VDACs) are a class of porin ion channel located in
the outer mitochondrial membrane [66]. They regulate the flux of proteins, small molecules and
ions between the cytosol and the mitochondria [67]. Additionally, they have been involved in
several key biologic processes such as energy metabolism, calcium transport and apoptosis [6771]. At near zero mitochondrial membrane potential, the VDAC pores open, and allow the
liberation of cytochrome c in the cytosol and trigger apoptosis[72-76]. Cisplatin has been shown
to bind VDACs and trigger cell death as a preliminary step in the apoptosis process prior to
cytochrome c release. Remarkably, VDAC-depleted cancer cells are highly resistant to cisplatin
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treatment [67, 69, 70, 77-79]. Several PK mechanisms appear to contribute to cisplatin-resistant
ovarian cancer, ranging from the downregulation of key membrane transporters such as CTR1, to
altered localization of ATP7A, to sequestration of activated cisplatin compounds [58, 59, 80-87].
Depletion of the VDACs have been reported in cervical and head and neck cisplatin-resistant
cancers, however, there is no direct evidence that this specific mechanism is linked to ovarian
cancer [76, 77]. Based on the available evidence, interplay of PK factors seems to contribute to
the suboptimal intracellular concentration of activated cisplatin, therefore establishing the
cisplatin-resistant EOC phenotype.
2) Activation of DNA repair
Three excision repair pathways exist to repair single stranded DNA damage: nucleotide
excision repair (NER), base excision repair (BER), and DNA mismatch repair (MMR). The bulk
of cisplatin lesions are removed from DNA by the NER system [88-90]. Damaged nucleotides
are excised from DNA upon incision on both sides of the lesion, followed by DNA synthesis to
reconstitute genetic integrity. Amplification of this process has been correlated with cisplatin
resistance in multiple preclinical models and validated clinically [91-93].

While the BER

pathway can recognize specific non-bulky lesions in DNA, it can correct only damaged bases
that are removed by specific enzymes. The MMR pathway only targets mismatched base pairs
that are seldom seen in cisplatin-induced DNA lesions, thus not proven to be a significant
mechanism of cisplatin resistance in that fashion [65, 94, 95]. The MMR-related proteins, MutL
(MLH) and MutS (MSH) which participate in the recognition of GpG inter-strand adducts, will
attempt to repair cisplatin adducts but fail, leading to apoptosis. Defects in MLH1 and MSH6
are associated with increased level of translesion synthesis, whereby DNA synthesis is not
blocked but proceeds beyond the cisplatin effects [96]. Indeed, methylation-dependent silencing
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of MLH1 has been shown to predict poor survival in ovarian cancer patients [97]. MLH1,
MSH2, and MSH6 are responsible for the hereditary nonpolyposis colon cancer syndrome
(HNPCC) including 2% of ovarian cancers patients. Interestingly, previous clinical report of
HNPCC-ovarian cancer patients suggests an association between the syndrome with decreased
response to cisplatin and aggressive tumor [98].
Cisplatin-induced inter-strand adducts can lead to the so-called double-strand DNA break
lesions that are normally repaired by homologous recombination machinery.

Two critical

components of the homologous recombination machinery system are encoded by BRCA1 and
BRCA2, two genes that are frequently mutated in familial breast and ovarian cancers. Although
BRCA1/2 tumors respond better to chemotherapy including cisplatin, additional mutations that
restore the function of the enzymes appear to confer resistance to platinum compound [99].
Altogether, these observations highlight the contributions of several of the DNA repair
mechanisms in cisplatin-resistant ovarian cancer. The above-mentioned studies, if validated in
clinical trials by other investigators, will pave the way for targeted interventions in order to
reverse the chemoresistance.
3) Decreased cell death
The process of apoptosis can be initiated by a diverse range of extracellular and
intracellular signals, that may positively or negatively affect the process itself [100-104]. Upon
stimulation, the cell undergoes organized degradation of cellular organelles by activated
proteolytic caspases.

Caspases are proteins that are highly conserved, cysteine-dependent

aspartate-specific proteases. There are two types of caspases: initiator caspases (caspase 2, 8, 9,
10) and effector caspases (caspase 3, 6, 7) [104]. The activation of initiator caspases requires
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binding to a specific oligomeric adaptor protein. Effector caspases are then activated by these
active initiator caspases through proteolytic cleavage.
Several proteins are involved in the apoptosis process, but two main methods of
regulation have been identified. The first (intrinsic) pathway targets mitochondria functionality
by directly transducing the signal via adaptor proteins to the apoptotic mechanisms [68, 102].
The second (extrinsic) death-receptor pathway, can be explained by two models, the tumor
necrosis factor (TNF)-induced and the Fas-Fas ligand (FasL)-mediated, both involving receptors
of the TNF receptor (TNFR) family coupled to extrinsic signals. The interaction between Fas
and FasL results in the formation of the death-inducing signaling complex (DISC), which
contains the FADD, caspase-8 and caspase-10.

Upon activation, a balance between pro-

apoptotic: Bcl-2-associated X protein (BAX), BH3 interacting-domain death agonist (BID), Bcl2 homologous antagonist killer (BAK), or Bcl-2-associated death promoter (BAD) and antiapoptotic: B-cell lymphoma-extra-large (Bcl-Xl) and B-cell lymphoma 2 (Bcl-2) members of the
Bcl-2 family is established.

The pro-apoptotic homodimers are required to make the

mitochondrial membrane permeable for the release of caspase activators such as cytochrome c
and small mitochondria-derived activator of caspases (SMAC). There also exist others like:
caspase-independent apoptotic pathway that is mediated by AIF, the endoplasmic reticulum (ER)
stress pathway, and the p53-dependant pathway. Alternatively, several anti-apoptotic pathways
have been described such as the receptor-associated mechanisms: the Decoy receptors, the
FLICE-like inhibitory protein (FLIP), the inhibitors of apoptosis proteins (IAP) family members,
nuclear factor-kappa beta (NF-kB) and its relative anti-apoptotic members, the phosphoinositide
3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway,
and the mitogen-activated protein kinases (MAPK) Pathways.
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Lethal cisplatin-induced DNA damage activates signaling cascades leading to apoptosis.
Genetic and epigenetic alterations in the components of this complex signaling network have
been associated with variable levels of resistance to cisplatin.

Reportedly, ovarian cancer

patients carrying wild-type TP53 have a higher probability to benefit from cisplatin-based
chemotherapy than patients with TP53 mutations [105, 106].
Autophagy involves cell degradation of unnecessary or dysfunctional cellular
components through the actions of lysosomes [107]. At the molecular level, several autophagyrelated genes (Atg) regulate this process that is known to be initiated from mTOR complex1derived stress signals [108]. Also, intact nuclear p53 positively influences autophagy through a
variety of ways[109]. Alternatively, autophagy can be more complex and specific involving a
chaperone-mediated pathway [110]. Autophagy has been linked to cisplatin resistance in both
ovarian and lung cancer cells by increasing the expression of key autophagy markers [111, 112].
Surprisingly, mTOR inhibitors paradoxically enhanced response to cisplatin in head and neck
carcinomas [111]. Other pathways implicating ER stress, chaperone mediated autophagy, among
others may play a role in response and resistance to cisplatin however; the precise mechanisms
are not yet clarified [113].
Modifications in cell signaling pathways or factors that regulate and execute apoptosis,
have the potential to influence cisplatin sensitivity. Several proteins (including death receptors,
cytoplasmic adaptors, pro- and anti-apoptotic members of the Bcl-2 protein family, caspases,
calpains, mitochondrial intermembrane proteins, and many others) have been shown to modulate
the response to cisplatin and other drugs [38, 79, 114-116].

However, only some predict

cisplatin responsiveness in the clinical setting and are undergoing clinical trials. For example,
conclusive clinical data on the association between the pro-apoptotic Bcl-2 family members
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BAX and BAK and cisplatin sensitivity are missing, but elevated levels of their anti-apoptotic
counterparts including Bcl-2, Bcl-Xl and myeloid cell leukemia sequence 1 (MCL-1) reportedly
correlate with cisplatin resistance and tumor recurrence in multiple clinical scenarios [117-120].
Altogether, these observations suggest that multiple factors are likely to affect the
molecular mechanisms that underlie cisplatin resistance.
4) Cancer stem cells
A growing body of evidence suggests that factors involved in cell pluripotency and selfrenewal, keys characteristics of stem cells, are implicated in cancer biology [7-19]. Indeed, since
the isolation of human embryonic stem cells (ESCs), significant interests have been generated in
science and medicine because of their therapeutic potential [121]. The genes and signaling
pathways that regulate the stem cell state are referred to as the “stemness” signature [122]. Selfrenewal and pluripotency is a complex process that demands the cooperation of both intrinsic
and extrinsic pathways to maintain the state of stemness and undergo clonal expansion [123-127].
The transcription factors Sox2, Nanog and Oct4 form the core regulatory positive feedback-loop
that sustains the stem cells capacity for self-renewal and pluripotency. Numerous pathways such
as Leukemia inhibiting factor (LIF), Notch, Sonic hedgehog (Shh) and Wnt signaling have also
been linked to tumorigenesis and stemness [128-136]. Cancer stem cells (CSCs) are thought to
be associated with poor outcomes such as high relapse rate and resistance to standard
chemotherapy [9-11, 137-139]. Both in human and animal models, Sox2 overexpression has
been associated with malignant tumor formation and poor outcomes in several cancers [8, 10,
138, 140-144]. When aberrations of these stemness regulatory pathways ensue as a consequence
of p53 mutations, massive clonal expansion of a malignant phenotype with self-renewal potential
becomes possible.
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Evidence suggests the existence of human OCICs with stemness properties and enhanced
resistance to cisplatin and paclitaxel [13]. The emergence of CSC subpopulations in a tumor
poses a real challenge since these cells can be slow growing and not affected by standard
chemotherapy. Reportedly, after initial response to chemotherapy, the repopulation of the tumor
bulk can occur, resulting progression and recurrence. The lack of improvement of overall
survival in EOC raises the possibility that other mechanistic pathways, not currently targeted, are
involved in the biology of the tumor.
5) Tumor microenvironment
The tumor microenvironment (TME) represents the intimate stroma that surrounds the tumor
and includes the surrounding blood vessels, and other connective tissue components such as: the
extracellular matrix (ECM), inflammatory cells, fibroblasts, bone marrow-derived inflammatory
cells; as well as immune cells, and signaling molecules [145, 146].

There is a dynamic

relationship between the TME and the tumor. The cells in the TME can affect the growth and
evolution of malignant cells; while the tumor cells, by releasing extracellular signals, promoting
tumor angiogenesis and induce peripheral immune tolerance. Several TME players have been
linked to chemoresistance as well as to the platinums. Here, we present a non-exhaustive
summary of original work studying this specific field.
Periostin (POSTN) is a human protein that functions as a ligand for alpha-V/beta-3 and
alpha-V/beta-5 integrins to support adhesion and migration of epithelial cells [147].

Its

overexpression in the cancer microenvironment, mediated by the AKT pathway, was found to be
correlated with poor prognosis in EOC patients and associated with platinum resistance [148].
Also, low-affinity leukotriene B4 receptor-2 (BLT2) and its ligand, leukotriene B4, were highly
upregulated in cisplatin-resistant SKOV-3 ovarian cancer cells and played critical roles in
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mediating the chemoresistance through the activation of signal transducer and activator of
transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6) [149].
Fibroblast activation protein alpha (FAP) is overexpressed by fibroblasts present in the
microenvironment of many tumors. FAP expression in EOC cells was found to be associated
with poorer clinical outcomes.

It was suggested that anti-FAP therapy could be a highly

effective novel treatment for EOC, especially in cisplatin-resistant cases [150].
Tumors can produce exosomes that stimulate inflammation via myeloid-derived
suppressor cells (MDSCs) [151]. This group of cells include tumor associated macrophages
(TAMs), mainly of the M2 phenotype, which is known to actively promote tumor growth [152].
Evidence suggests that resistance to chemotherapy is associated with increased levels of IL-6 and
prostaglandin E2 (PGE (2)), two inflammatory mediators known to skew differentiation of
monocytes to M2 macrophages. Treatment with cyclooxygenase-inhibitor and/or monoclonal
antibody against interleukin-6 receptor (IL-6R) prevented M2-differentiation [153].
The COL6A3 gene encodes the alpha-3 chain of collagen type VI. It is responsible for
microfibril formation and extracellular matrix communication [154, 155]. Differential gene
expression profiling identified COL6A3 as one of the most highly upregulated genes in cisplatinresistant ovarian cancer cells compared to their cisplatin-sensitive counterparts [156].

The

authors suggest that tumor cells may directly remodel their microenvironment to increase their
survival in the presence of chemotherapeutic drugs [156].
Ultimately, we have recently demonstrated that angiogenesis was impaired in
chemoresistant EOC cells, and suggested that the lack of drug delivery to the tumor site as a
potential mechanism for the emergence of the chemoresistant phenotype [157]. Although the
contribution of the TME in the establishment of chemoresistance in several tumors has been
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suggested, however, conclusive evidence supporting the associations between cisplatin-resistant
ovarian cancer and the various components of the TME is still lacking.
6) Oxidative stress
Clinical, epidemiological and basic science investigations have provided evidence
supporting the role of ROS and RNS in the etiology of cancer [58, 158-164]. Oxidative stress is
defined as an imbalance between the production of oxidants and the biological system’s inability
to eliminate these oxidants by antioxidants [165].
Oxidative stress and ovarian cancer
Oxidative stress has been implicated in the pathogenesis of several malignancies including
ovarian cancer [166, 167]. Moreover, there is evidence that ovarian cancer patients also have
decreased levels of circulating antioxidants [167].

Reactive species (both ROS and RNS)

including superoxide (O2●−), hydroxyl radical (HO●), hydrogen peroxide (H2O2), peroxynitrite
(ONOO−), nitric oxide (NO) and, hypohalous acids are free radical molecules that are highly
destructive to cellular functions [168, 169]. Various enzyme systems produce ROS including the
mitochondrial electron transport chain, cytochrome P450, lipoxygenase, cyclooxygenase, the
NAD(P)H oxidase complex, xanthine oxidase (XO), and peroxisomes [170, 171]. Mitochondrial
O2 metabolism is the dominant source of O2●− that results from incomplete coupling of electrons
and H+ with O2 in the electron transport chain. Under normal conditions, ROS and RNS are
maintained within narrow parameters by scavenging systems, as would be expected where those
enzymes are involved in cell signaling, while ROS/RNS formed after exposure to oxidative
stress can activate signaling molecules [159, 170-177]. The redox balance is maintained by
various enzyme systems that neutralize toxic reactive oxygen and nitrogen species. Superoxide
dismutases (SOD) catalyze the conversion of O2●– to H2O2, which then can be converted to water
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by catalase (CAT) or glutathione peroxidase (GPx) coupled with glutathione reductase (GSR)
[178]. Other important scavengers include thioredoxin coupled with thioredoxin reductase, and
glutaredoxin, which utilizes GSH as a substrate. Additionally, glutathione S transferase (GSTs)
are involved in detoxification of varieties of environmental carcinogens and xenobiotics by
catalyzing their conjugation to GSH, and subsequent removal from the cell [179]. Glutathione
plays a central role in maintaining redox homeostasis, and the GSH-to-oxidized-GSH ratio
provides an estimate of cellular redox buffering capacity [170, 180].

Moreover, evidence

suggests that increase in oxidative stress mediated by the GSH/GSSG complex results in
enhanced activity of GS-X-MRP1 efflux pump.

This pump is known to decrease the

intracellular effective drug concentration, therefore is considered one of the mechanisms of
multiple drug resistance including platinum compounds [181-184].
Cancer cells are known to be under intrinsic oxidative stress resulting in increased DNA
mutations or damage, genome instability, and cellular proliferation [46, 178, 185-187]. The
persistent generation of cellular ROS is a consequence of many factors including exposure to
carcinogens, infection, inflammation, environmental toxicants, nutrients, and mitochondrial
respiration [188-191].

Nitration of tyrosine residues to 3-nitrotyrosine, a hallmark of

inflammation as well as a footprint of many types of oxidative injury, may play a role in the
pathogenesis of human ovarian cancers [192]. Specifically, an increased expression of prooxidant enzymes such as inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO),
NAD(P)H oxidase, as well as an increase in NO as indicated by increased nitrate/nitrite
(NO3−/NO2−) has been shown in EOC tissues and cells [193-195]. Also, EOC cells manifested
lower apoptosis, which was markedly induced by inhibiting iNOS by L-NAME, indicating a
strong link between apoptosis and NO/iNOS pathways in these cells [194]. Myeloperoxidase
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utilizes NO, produced by iNOS, as a one-electron substrate generating NO+, a labile nitrosating
species that is rapidly hydrolyzed forming NO2− as an end product [196-199]. The ability of
MPO to generate NO+, from NO, led us to believe that not only does MPO play a role in Snitrosylation of caspase-3, thus inhibiting caspases-3 activity, which is indicative of lower
apoptosis in EOC cells, but also highlights a possible cross-talk between iNOS and MPO [193].
Myeloperoxidase, an abundant hemoprotein previously believed to be present solely in
neutrophils and monocytes, plays an essential role in immune surveillance and host defense
mechanisms, and can contribute to 3-nitrotyrosine formations in vivo and directly modulate
inflammatory responses via regulation of NO bioavailability during inflammation [192, 200].
Silencing MPO gene expression utilizing MPO specific siRNA induced apoptosis in EOC cells
through a mechanism that involved S-nitrosylation of caspase-3 by MPO [193]. Additionally,
we have compelling evidence that leads us to believe that MPO may serve as a source of free
iron under oxidative stress, where both NO and O2●– are elevated [201]. Iron reacts with H2O2
and catalyzes the generation of highly reactive HO●, thereby increasing oxidative stress, which in
turn increases free iron concentrations by the Fenton and Haber–Weiss reaction [202].
Collectively, we now have substantial evidence to believe that altered oxidative stress
may play a role in maintaining the oncogenic phenotype of EOC cells.

In addition,

epidemiologic studies have demonstrated the role of family history as an important risk factor for
ovarian cancer [203]. Mutations in BRCA genes are currently utilized to evaluate risk for breast
and ovarian cancer, however, are not ideal because the mutations are so rare (1 out of 500
individuals), thus, the overall impact on mortality is small [204]. Additionally, the burden of
cancer is being correlated with common, weakly penetrant alleles that are often classified as
sporadic (i.e. without a heritable basis) [204].

Non-synonymous single nucleotide
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polymorphisms (SNPs) substitute encoded amino acids in proteins, and are more likely to alter
the structure, function, and interaction of the protein [205]. Therefore SNPs are good candidates
as disease-modifiers and have been associated with an altered cancer risk [205].
We have recently characterized EOC tissues and cells to manifest a persistent pro-oxidant
state with the upregulation of several key oxidant enzymes including: myeloperoxidase (MPO),
inducible nitric oxide synthase (iNOS), and nicotinamide adenine dinucleotide phosphate
(NAD(P)H) oxidase with concurrent decrease in apoptosis compared to normal human ovarian
tissues and cells. More importantly, shutting down the expression of one or more of these key
oxidant enzymes reduced the pro-oxidant state, and significantly induced apoptosis. Singlenucleotide polymorphisms (SNPs) are point mutations that are selectively maintained in
populations and are distributed throughout the human genome at an estimated overall frequency
of at least one in every 1000 base pairs. Several SNPs in key oxidants and antioxidants enzymes
have been associated with various cancers including ovarian. Therefore, we are proposing the
following hypothesis: cisplatin treatment induces mutations in key oxidant and antioxidant
enzymes resulting in further enhancement of oxidative stress and the acquisition of resistance in
EOC cells. To test this hypothesis, we are proposing then following specific aims:
Specific Aim 1: To determine the association of specific single nucleotide polymorphisms
(SNPs) in key oxidant and antioxidant enzymes with EOC risk and survival in patients.
The rationale of this aim is based on the fact that oxidative stress is strongly associated
with several cancers, including ovarian. Known specific SNPs in oxidant and antioxidant genes
may alter their expression profile and enzymatic functions. These SNPs have been reported to be
associated not only with cancer risks, but also patient response to treatment and survival. The
hypothesis of this aim is that specific SNPs in key oxidant and antioxidant enzymes are
associated with overall patient survival. To achieve this aim, we will perform a case-control
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study using stored blood samples of research participants from the Karmanos Cancer Center.
Individuals (n=143) recruited were divided into controls (n=94),) and ovarian cancer cases
(n=49). Samples will undergo DNA extraction followed by TaqMan® SNP genotype analysis
for rs4880 manganese superoxide dismutase (MnSOD), rs4673 (NAD(P)H oxidase (CYBA),
rs3448 glutathione peroxidase (GPX1), rs2297518 inducible nitric oxide synthase (iNOS),
rs1002149 glutathione reductase (GSR), and rs1001179 catalase (CAT). We will perform a
multivariate analysis for identification of confounding variables and potential predictors of risk.
Additionally, to study the impact of the SNPs on overall survival, Cox regression and KaplanMeier survival analyses will be used.
Specific Aim 2: To determine the association of key oxidant and antioxidant enzymes as
well as specific SNPs in these enzymes with the development of cisplatin resistance in EOC
cells.
The rationale of this aim is based on previous findings showing an association between
the altered redox enzymes and EOC, in both patients and human cell lines. The hypothesis of
this aim is that the acquisition of resistance to cisplatin in EOC cells is associated with enhanced
pro-oxidant profile, as well as specific SNPs in key oxidant and antioxidant enzymes. To achieve
this aim, we will utilize two human EOC cell lines, MDAH-2774 and SKOV-3 and their
cisplatin resistant counterparts. We will perform TaqMan PCR genotyping, real-time RT-PCR,
ELISA, and Griess assay to study the expression profile of the following genes: CYBA/NOX4,
iNOS, CAT, SOD3, GSR and GPX1. To analyze the difference in the expression profiles of these
genes for sensitive compared to resistant cells, we will use a Student’s t-test.
Specific Aim 3: To determine whether specific SNP(s) in key oxidant and antioxidant
enzymes cause the acquisition of cisplatin resistance in EOC cells.
The rationale of this aim is based on the established fact that cisplatin treatment causes
DNA damage, and the observation that specific SNPs in the redox enzymes were found to be

18
associated with poor survival in patients. The hypothesis of this aim is: specific SNPs in key
oxidant and antioxidant enzymes cause cisplatin resistance. To achieve this aim, we will utilize
the CRISPR/Cas9 system to generate point mutations in sensitive EOC cells corresponding to the
SNP genotype of the chemoresistant MDAH-2774 and SKOV-3 EOC cells. The cells will then
be tested for cisplatin resistance using the MTT viability assay using the IC50 method. Results
will be analyzed with regression analysis and student t-tests.
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CHAPTER 2: GENERAL METHODS
Cell Culture
This is a well-established technique in our laboratory [193]. Human EOC cell lines,
MDAH-2774 (CRL-10303) and SKOV-3 (HTB-77), were obtained from American Type Culture
Collection (ATCC, Manassas, VA). The MDAH-2774 cell line was developed from ascitic fluid
cells from a patient with adenocarcinoma in 1972, and forms tumors in nude mice [206]. SKOV3 cells were developed from ascitic fluid of a 64-year-old Caucasian female. Cell lines are
cultured in McCoy’s 5A medium (Invitrogen, Carlsbad, CA) supplemented with 100 U/mL
penicillin and 100 µg/mL streptomycin and 10% heat-inactivated fetal bovine serum (FBS) at
37°C in 5% CO2.
Two parent human EOC cell lines (SKOV-3 and MDAH-2774) were utilized in
developing cells resistant to cisplatin. Cells were exposed to a stepwise increase in cisplatin
(Sigma Aldrich, St Louis, MO) over the course of a year, with final cisplatin IC50 concentrations
of 1.87 μM and 3.31 μM for SKOV-3 and 1.70 μM and 6.34 μM for MADH-2774, sensitive and
resistant respectively. The Trypan Blue Dye Exclusion Method was used to confirm resistance
as follows: once the desired level of resistance was achieved, a 2-week incubation period without
cisplatin and subsequent reintroduction of cisplatin was performed. Resistance was confirmed
with the Vybrant® MTT Cell Proliferation Assay Kit (Life Technologies, Carlsbad, CA),
according to the manufacturers protocol. The IC50, concentration of the drug at which 50% of
the cells are alive, was determined using regression analysis of the MTT dose-response cell
proliferation assay.
Protein Extraction
Cell lysates were prepared utilizing cell lysis buffer (Cell Signaling Technology, Danvers,
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MA) supplemented with Protease Arrest (G-Biosciences, St. Louis, MO).

Total protein

concentration of cell lysates was measured with the Pierce BCA Protein Assay Kit (Thermo
Scientific, Rockford, IL) per the manufacturer’s protocol.
Purification of DNA and the TaqMan SNP Genotyping Assay for SNPs
DNA, from blood samples or cells, was isolated by the Applied Genomics Technology
Center (AGTC, Detroit, MI).

DNA was extracted with QIAamp DNA mini kit per the

manufacturer’s protocol (Qiagen, Valencia, CA) [207]. The TaqMan® SNP Genotyping Assay
Sets (Applied Biosystems, Carlsbad, CA) (NCBI dbSNP genome build 37, MAF source 1000
genomes) were used to genotype selected SNPs described in Table 1. The AGTC performed this
assay and analysis was done utilizing the QuantStudio™ 12K Flex Real-Time PCR System
(Applied Biosystems).
Table 1: Characteristics of single nucleotide polymorphisms examined for genotyping.
SNP

NCBI MAF

Chromosomal
location

Known AA
Switch

Effect on activity

CAT (rs1001179)

C-262T

0.123

11p13

Unknown

Decrease

CYBA (rs4673)

C242T

0.303

16q24.3

Tyr to His

Decrease

GPX1 (rs3448)

C-1040T

0.176

3p21.31

Unknown

Unknown

GSR (rs1002149)

G201T

0.191

8p12

Unknown

Unknown

SOD2 (rs4880)

T47C

0.371

6q25.3

Val to Al

Decrease

T-764C

0.23

17q22

Unknown

Decrease

Gene (RS)

MPO (rs2243828)

NOS2 (rs2297518)
C2087T
0.173
17q11.2
Ser to Leu
Increase
AA; amino acid, Ala; alanine, CAT; catalase, CYBA; NAD(P)H oxidase subunit (NOX4), GSR; glutathione
reductase, GPX; glutathione peroxidase, His; histidine, Leu; leucine, MAF; minor allele frequency, SOD2;
manganese superoxide dismutase, MPO; myeloperoxidase, NCBI; National Center for Biotechnology Information,
NOS2; nitric oxide synthase, Ser; serine, SNP; single nucleotide polymorphism, Tyr; tyrosine, Val; valine.

ELISAs
Unless otherwise stated, all assays were performed utilizing cell lysate according to the
manufacturer’s protocols.
The Superoxide Dismutase Assay Kit (Cayman Chemical, Ann Arbor, MI) detects SOD
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activity by measuring the dismutation of O2●− generated by XO and hypoxanthine. The standard
curve generated using this enzyme provides a means to accurately quantify the activity of all
three types of SOD (Cu/Zn-, Mn-, and Fe-SOD). One unit of SOD, detected at 460 nm, is
defined as the amount of enzyme needed to exhibit 50% dismutation of O2●−.
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CHAPTER 3: RISK AND SURVIVAL ASSOCIATIONS BETWEEN SPECIFIC SNPS IN
OXIDANT AND ANTIOXIDANT ENZYMES AND PATIENTS WITH EPITHELIAL
OVARIAN CANCER
(This chapter contains previously published material [208]. See Appendix B)
Abstract
We sought to evaluate the association of SNPs in key oxidant and antioxidant enzymes
with increased risk and survival in patients with EOC. The rationale for this part of the study is
based on the fact that oxidative stress is strongly associated with several cancers, including
ovarian. Known specific SNPs in oxidant and antioxidant genes may alter their expression
profile and enzymatic functions. These SNPs have been reported to be associated not only with
cancer risks, but also patient response to treatment and survival. The hypothesis is that specific
SNPs in key oxidant and antioxidant enzymes are associated with a pro-oxidant profile, ovarian
cancer risk and overall patient survival. We performed a case-control study using stored blood
samples of research participants from the Karmanos Cancer Center. Individuals (n=143)
recruited were divided into controls (n=94) and ovarian cancer cases (n=49). Samples were
subjected to DNA extraction followed by TaqMan® SNP genotype analysis for rs4880 SOD2,
rs4673 CYBA, rs2333227 MPO, rs3448 GPX1, rs2297518 iNOS, rs1002149 GSR, and rs1001179
CAT. We have performed a multivariate analysis for identification of confounding variables and
potential predictors of risk. Additionally, to study the impact of the SNPs on overall survival,
Cox regression and Kaplan-Meier survival analyses were done.
Introduction
Epidemiologic studies have clearly established the role of family history as an important
risk factor for both breast and ovarian cancers [203]. Mutations in BRCA are currently utilized to
evaluate risk for breast and ovarian cancer. They are not ideal because the mutations are so rare
(1 out of 500 individuals), thus, the overall impact on mortality rate is small [204]. Genomic
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variations between individuals have been increasingly used in the practice of medicine [209-213].
A SNP occurs because of point mutations that are selectively maintained in populations and are
distributed throughout the human genome at an estimated overall frequency of at least one in
every 1000 base pairs [214]. Non-synonymous SNPs substitute encoded amino acids in proteins,
and are more likely to alter the structure, function, and interaction of the protein [215]. Recent
evidence demonstrates an association between enzymatic activity altering SNPs in oxidative
DNA repair genes and antioxidant genes with human cancer susceptibility [216]. Additionally, a
pro-oxidant state has been implicated in the pathogenesis of several malignancies, including
ovarian cancer [166, 195]. The current study is based on the fact that certain SNPs present in
key oxidants and antioxidants enzymes result in altered enzymatic activity as well as our
previously published work delineating the role of oxidative stress in ovarian cancer. Recently, a
SNP in MPO (rs2333227), which confers a decreased MPO activity, has been associated with
early stage ovarian cancer such that those with the G allele are at an increased risk for ovarian
cancer [217-219]. Additionally, a SNP in SOD2 has also been associated with increased risk for
ovarian cancer [219]. Increased enzyme activity is also associated with a SNP in iNOS (NOS2,
rs2297518) [220]. An increase in NAD(P)H oxidase activity has been associated with a specific
SNP in the CYBA gene (rs4673) and is also associated with an increased risk for other diseases
where oxidative stress plays a critical role in their pathophysiology, including cardiovascular
disease, asthma, and diabetic nephropathy [221-223]. A SNP in CAT (rs1001179) and MnSOD
(SOD2, rs4880), also result in a decreased enzyme level of CAT and activity of SOD [224-226].
We have selected several SNPs in key oxidant and antioxidant enzymes based on their effect on
function or association with cancer.
This chapter summarizes our efforts to determine whether specific SNPs in key oxidant
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and antioxidant enzymes are associated with the increased risk as well as overall survival of
ovarian cancer patients.
Methods
Human Subjects
Specimens were collected according to the Wayne State University Human Subject
Committee (IRB) protocol number 1102009344, IRB# 024199MP2F(5R), expiration date
01/11/13.
Women and Minorities
This study includes samples from women as it is assessing a gender specific disorder of
which many are minorities commensurate with the clinical population which is 82% AfricanAmerican’s in the city of Detroit, where Wayne State University and the Karmanos Cancer
Center are located.
Study design
We performed a case-control study comparing female subjects with and without EOC and
determined whether there is an association with several selected SNPs in established redox genes.
Eligible women were 19 to 80 years of age and were previously recruited through the Karmanos
Cancer Institute’s Genetic Registry (KCIGR), Detroit, MI. Research activities and method of
consent were conducted with the approval of Wayne State University Institutional Review Board
(IRB#024199MP2F(5R)). Informed written consent forms were utilized and permission was
granted for the collection of blood samples and for access to medical records for all subjects.
Patient Population
Recruited individuals (n=143) were divided into controls (94), which include: healthy
volunteers (n=18), high-risk BRCA1/2 negative (n=53), high-risk BRCA1/2 positive (n=23) and
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ovarian cancer cases (n=49).

Controls were selected primarily from research subjects,

considered high-risk for breast and ovarian cancers, without ovarian cancer that underwent
genetic screening for BRCA1/2 carrier status. Of note, the criteria used for screening included
personal history of breast and ovarian cancers, family histories of breast and ovarian cancers, and
BRCA1/2 mutations. Additionally, healthy volunteers were also recruited as controls from the
metropolitan Detroit area with no such histories. Cases were selected based on histopathologyconfirmed primary diagnosis of EOC. All participants, except healthy volunteers, had previously
undergone BRCA1/2 testing and the results were made available to us.
Samples used for this study were collected from participants recruited between 1999 and
2012. DNA samples were utilized to determine the presence of polymorphisms in the genes
described in Table 1. The SNPs were chosen based on previously reported associations with
several cancers [227-235]. Of the 143 subjects, 49 (34.3%) had a primary diagnosis of ovarian
cancer while 94 (65.7%) without cancer served as controls. For the ovarian cancer cohort: 13
(26.5%) were BRCA1/2 positive as compared to 34 (69.4%) BRCA1/2 negative; 2 (4.1%) cases
were missing. The data is normally distributed with the age of enrollment ranged from 18 to 90
with a mean of 52 ± 15 and a median age of 52. The age at diagnosis ranged from 23 to 77, with
a mean of 52 ± 11 and a median age of 52. The racial distribution was 88.8% (Caucasian), 8.4%
(African-American) and 2.8% (Other). Personal and family histories of breast cancer, ovarian
cancer, other cancers, and BRCA1/2 were quantified. The frequencies of the presence of the SNP
(heterozygous plus homozygous mutant) compared to homozygous wild type were determined
for each gene studied.
Purification of DNA and the TaqMan SNP Genotyping Assay for SNPs
DNA, from blood samples, was isolated by the Applied Genomics Technology Center
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(AGTC, Detroit, MI) and TaqMan was performed as described in General Methods.
Statistical analysis
Data were analyzed using SPSS (IBM, Armonk, New York) for Mac V.22. The following
tests were conducted: descriptive statistics, multivariate analysis, Cox regression and KaplanMeier survival analyses. The variables selected for the analyses include genotypes, age at
diagnosis, and age at enrolment, personal and family histories of breast, ovarian, and BRCA1/2
mutations, in addition to other malignancies. Using the median age at diagnosis/enrolment as a
cut point, we dichotomized the “age at diagnosis” variable. The “race” variable was categorized
as: Caucasian, African-American or Other. We consolidated the following tumor and clinical
variables into binary categorical schemes: International Federation of Gynecology and Obstetrics
(FIGO) stages into early (IIA-IIIB) and advanced (IIIC-IV); FIGO grades (G1/2) and (G3);
histology (serous and other).

For all the genes studied, the “genotype” variable was

dichotomized using the following scheme: homozygous wild type versus homozygous mutant
plus heterozygous mutant. To compare cases to controls on the selected demographic, clinical,
and genotypic characteristics, we performed Pearson Chi-square analysis. The recurrence rate
was determined as the percentage of patients that have gone into remission, but the disease has
returned months or years later, based on physical examination, radiological studies and serum
CA-125 levels.
Cox regression and Kaplan-Meier analyses of variables as a predictor of overall survival
To study the impact of the SNPs on overall survival, Cox regression analyses were
performed using the above-listed variables and classification schemes, using the likelihood ratio
forward stepwise method. Several method simulations were performed such as: forced entry
(ENTER), forward LR (likelihood ratio), etc. The forward LR was chosen for the final analysis.
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This method is a stringent model that selects the strongest predictors of the outcome to be
included in the final model.

All patients received the standard of care after tumor board

discussion. Details on treatment characteristics were not available. Additionally, Kaplan-Meier
survival curves were generated for the variables selected by the model. Statistical significance
was established at P-value less than 0.05 for all analyses.
Results
We performed side-by-side comparison between ovarian cancer cases and controls using
Pearson chi-square analysis. Racial distribution was statistically similar between the groups
(P>0.05). As expected, “personal or family history of ovarian cancer”, “personal or family
history of other cancers” and “advanced age” were significantly different between the groups and
Table 2. Comparison of cases and controls based on demographic, personal or family history
of cancer, and genotypic characteristics.
Controls %

Ovarian Cancer %

P-value
(Pearson Chi-square, 2-tailed)

n (76)
n (49)
<0.001*
Age at enrolment (n=125)
< median
51 (67.1)
8 (16.3)
> median
25 (32.9)
41 (83.7)
n (94)
n (49)
0.365
Race (n=143)
Caucasian
81 (86.2)
46 (93.9)
African-American
10 (10.6)
2 (4.1)
Other
3 (3.2)
1( 2.0)
n (94)
n (49)
Personal / Family History of Cancer (Yes)
Breast (n=105)
67 (71.3)
38 (77.6)
0.480
Ovarian (n=81)
33 (35.1)
48 (98.0)
<0.001*
BRCA1/2 (n=23)
18 (19.1)
5 (10.2)
.168
Other Cancer (n=69)
39 (44.3)
30 (62.5)
.043*
SNP (Yes)
NOS2 (n=49)
34 (37.4)
15 (30.6)
0.424
CYBA (n=92)
57 (60.6)
35 (71.4)
0.201
MPO (n=56)
36 (39.1)
20 (41.7)
0.771
GSR (n=36)
27 (30.3)
9 (19.6)
0.180
GPX1 (n=61)
40 (43.5)
21 (42.9)
0.943
CAT (n=49)
30 (31.9)
19 (38.8)
0.412
SOD2 (n=103)
66 (72.5)
37 (75.5)
0.703
*P < 0.05, 0.05, CAT; catalase, CYBA; NAD(P)H oxidase subunit (NOX4), GPX; glutathione peroxidase, GSR;
glutathione reductase, MnSOD; manganese superoxide dismutase, MPO; myeloperoxidase, NOS2; inducible nitric
oxide synthase.

are known ovarian cancer risk factors (p < 0.05, Table 2). Comparative analyses for MnSOD,
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rs4880, CYBA, rs4673, GPX1, rs3448, NOS2, rs2297518, MPO, rs2243828, GSR, rs1002149,
and CAT, rs1001179 did not find a significant difference between the cases and controls (Table
2). Out of the 49 ovarian cancer cases, 38 (77.5%) were further analyzed by the Cox regression
method, and 11 (22.5%) were dropped due to missing data. The majority of the cases were
serous histology, advanced stage, and high-grade tumors (Table 3). The recurrence rate was
found to be 60.5%.
Table 3. Stage, grade and pathologic characteristics of the cancer cases.
Tumor characteristics
Stage (n=38)
IA-IIIB
IIIC-IV
Total
Grade (n=38)
G1/2
G3
Total
Histology (n=38)
Serous
Clear cell
Endometrioid
Total

Number (%)
10 (26.3)
28 (73.7)
38 (100)
6 (15.8)
32 (84.2)
38 (100)
34 (89.5)
1 (2.6)
1 (2.6)
38 (100)

The CAT SNP is a predictor of shorter survival
At the time of these analyses, there were 26 deaths (18.2%) and 117 (81.8%) subjects
alive. Among the SNPs examined, only CAT (rs1001179) was identified as a predictor of shorter
survival by the Cox regression model with a hazard ratio (HR) of 3.68 (95% CI: 1.149-11.836,
p=0.028) (Table 4). As expected, “age at diagnosis” greater than the median (52) was found to
be a significant predictor of death with an HR of 2.78 (95% CI: 1.022-7.578, p=0.045) (Table
4A). The variables selected for the analyses, but rejected by the model are listed in Table 4B.
Table 4A. Cox regression forward likelihood ratio (LR).
Variables in the Equation

Age at Diagnosis > Median
CAT (CT+TT)

Significance
.045*
.028*

HR
2.782*
3.688*

95% CI for HR
Lower
Upper
1.022
7.578
1.149
11.836
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Table 4B. Variables analyzed by cox regression but rejected by the model.
Variables not in the Equation
Score

Race (Caucasian)
Stage (III-IV)
Grade (high)
GSR (CT+TT)
GPX1 (CT+TT)
MnSOD (CT+TT)
NOS2 (CT+TT)
CYBA (CT+TT)
MPO (CT+TT)
Histology (serous)

Significance

.580
.708
.708
.411
.000
1.020
2.084
1.229
.178
1.016

.446
.400
.400
.522
.988
.312
.149
.268
.673
.314

Kaplan-Meier (K-M) survival analysis factored by CAT genotype, which used 84.6% of
the deaths, demonstrated a statistically significant median overall survival difference (108 [95%
CI: 79-137] versus 60 [95% CI: 40-80] months, P<0.05) and a mean overall survival difference
(182 [95% CI: 75.5-288] versus 47 months [95% CI: 31-60], P<0.05) for subjects with the
normal genotype as compared to the CAT SNP genotype (Figure 2).
Figure 2. Kaplan-Meier overall
survival curves for ovarian cancer
patients utilizing a specific catalase
SNP. The solid curve represents cases
with (CC) homozygous wild-type
genotype as compared to the dashed
curve, which represents cases with
homozygous
mutant
plus
heterozygous
mutant
(CT+TT)
genotypes. The X-axis represents
patient survival in months; the Y-axis
represents
cumulative
survival
percentage. Chi-square P-value < 0.05
is considered statistically significant.

Log Rank (Mantel-Cox) p-value = .004, Chi-Square = 8.32
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Discussion
A large body of evidence suggests that ovarian cancer patients have decreased levels of
circulating antioxidants and higher levels of oxidative stress [23, 166, 167, 178, 193, 195, 236].
We have reported the existence of a persistent pro-oxidant state in EOC that included increased
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expression of key pro-oxidant enzymes such as iNOS, NAD(P)H oxidase, and MPO [193-195].
Interestingly, the expression of MPO in EOC cells and tissues came as a surprise as it is an
oxidant-generating enzyme typically found in cells of myeloid origin [217]. We have also
determined that MPO can produce the nitrosonium cation (NO+) utilizing NO produced by iNOS.
This is important because NO+ causes s-nitrosylation of caspase-3, and inhibition of its activity,
resulting in a decrease in apoptosis [193]. This mechanism further explains the observation that
EOC cells manifest significantly decreased apoptosis and increased survival [193, 194, 197, 198].
Interestingly, the evaluation of mutations in the various redox enzymes in the form of SNPs is an
active area of scientific research [237-245]. Genetic polymorphisms are known to be associated
with cancer susceptibility and can be determined by studying functional polymorphisms in genes
that control the levels of cellular reactive oxygen species and oxidative damage, including SNPs
for genes involved in carcinogen metabolism (detoxification and/or activation), antioxidants, and
DNA repair pathways [246].

For example, germline mutations in BRCA1 or BRCA2 are

associated with ovarian cancer at a rate of only 20-40%, suggesting the presence of other
unidentified mutations in other genes as an etiology [215, 247, 248].

Additional genetic

variations, many of which have been identified in recent genome-wide association studies
(GWAS), have been hypothesized to act as low to moderate penetrant alleles, which contribute to
ovarian cancer risk, as well as other diseases [215, 249]. In support of this, recent studies have
also associated genetic polymorphisms in genes involved in suppression of tumorigenicity as
well as those involved in cell cycle with ovarian cancer [250, 251].
For this study, we sought to evaluate the association of specific SNPs in key oxidant and
antioxidant enzymes with increased risk and overall survival of ovarian cancer. The analysis of
the patient population revealed that the average age at diagnosis and racial distribution of those
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diagnosed with ovarian cancer were consistent with known risk factors for ovarian cancer,
specifically, women of North American decent and those over 50 years old. Currently we
demonstrated that there is no association between the selected SNPs and risk of developing
ovarian cancer (Table 2). It is important to emphasize the fact that although the selected SNPs
for this study were not found to be associated with ovarian cancer risk, additional change of
function SNPs for these enzymes exist and should be explored further. Of the SNPs studied when
examining survival, we found the CAT SNP (rs1001179) to be a significant predictor of death
when present in ovarian cancer patients as illustrated by the Cox regression and K-M survival
analyses (Table 4A and Figure 2). Specifically, ovarian cancer patients with the CAT SNP died
significantly sooner than those without it (Figure 2). The CAT SNP (rs1001179) is found in the
promoter region of the CAT gene, substituting allele C with T at position -262 in the 5’ region of
chromosome 11 and is correlated with decreased enzyme activity level [224]. Catalase is a very
important and ubiquitous enzyme involved in the degradation of two molecules of H2O2 to water
and oxygen. The current findings are consistent with several other studies, which linked this
specific SNP with risk, response to adjuvant treatment and survival of cancer patients [227, 228,
233, 252]. Specifically, low serum CAT levels were associated with adverse prognosis for
ovarian cancer [230]. Our data provides a possible explanation for low serum CAT levels, which
may be a result of a CAT SNP that lowers enzymatic activity. Moreover, mechanistic studies
have identified H2O2, a result of oxidative stress, enhance angiogenesis and tumor invasiveness
through several pathways including: hypoxia inducible factor 1-alpha, p38 MAPK and snail [253,
254]. It appears that the final common pathway culminates to epidermal growth factor (EGF)induced down-regulation of epithelial cadherin expression that can be inhibited by exogenous
CAT [253]. Epithelial-cadherin is a cell-cell adhesion glycoprotein encoded by the CDH1 gene
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in humans, which has been characterized as a tumor suppressor [255, 256]. Its loss of function is
correlated with several solid tumors including ovarian and thought to contribute to tumor
progression and metastasis [257].
It is important to emphasize that the lack of association between the selected SNPs in this
study with ovarian cancer risk does not definitively answer this important question because
additional change-of-function SNPs for these enzymes exist and should be explored further.
Recent genetic studies have linked MPO to lung and ovarian cancers by demonstrating a striking
correlation between the relative risk for development of the disease and the incidence of
functionally distinct MPO polymorphisms [258]. In breast cancer, the presence of the CAT SNP
(rs1001179), was shown to confer increased risk [233]. We have selected numerous additional
SNPs based on their effect on enzyme activities or association with cancer. Several SNPs in
NOS2 have been associated with gastric, esophageal, skin and urogenital cancers [229, 231].
Also, SNPs in MnSOD, GPX1, GPX4, CAT were found to be associated with prostate cancer
[233].
Other studies have found a SNP in SOD2 (rs4880) and a SNP in MPO (rs2333227) to be
associated with increased risk for ovarian cancer [217]. The MPO SNP we have analyzed in this
study is in 100% concordance with SNP rs2333227 [259]. Thus, in addition to examining other
changes of functional SNPs, increasing the size of our cohort may be sufficient to reach
statistical significance in several of the SNPs chosen for this study. The strength of our study
includes the comprehensive nature of redox genes studied and the translational aspect of our
approach by assessing simultaneously clinical and genotypic characteristics of the population.
We believe the fact that our control cohort is heterogeneous represents strength, because it
includes patients considered at high risk for BRCA1/2 mutation and those without any
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established risk factors for ovarian cancer, reflecting the baseline risk group (general population).
Interestingly, patients who tested negative for BRCA1/2 mutations, as well as, those with family
history of BRCA1/2 mutations but also tested negative for BRCA1/2 should be considered at a
higher risk profile than the general population. More importantly, to our knowledge, we are the
first to report an association between the presence of this specific CAT SNP and ovarian cancer
survival. The study has several limitations such as small sample size, the retrospective nature
inherent to case-control studies, and the geographic restriction of the population. In our patient
population, the recurrence rate was found to be 60.5%; however, the exact date of recurrence was
not established making the computation of progression-free survival (PFS) impossible. We
acknowledge that the determination of PFS would have strengthened our findings as PFS has
often been used as a primary endpoint or a surrogate to overall survival in clinical trials [260265].
It is now evident that oxidative stress plays a major role in the pathogenesis of cancer
including ovarian. The exact mechanisms remain to be clarified. In this preliminary study we
were able to show that a specific CAT SNP is associated with poor survival in ovarian cancer
patients. Further studies examining other SNPs in key oxidants and antioxidant enzymes with
higher number of patients will be needed to establish this link. SNPs in these enzymes may serve
as potential markers for ovarian cancer, which are urgently needed. Our study indicates a strong
association with the CAT SNP and survival of ovarian cancer patients, and thus may serve as a
prognosticator.
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CHAPTER 4: ASSOCIATION BETWEEN KEY OXIDANT AND ANTIOXIDANT
ENZYMES AS WELL AS SPECIFIC SNPS IN THESE ENZYMES WITH THE
DEVELOPMENT OF CISPLATIN RESISTANCE IN EPITHELIAL OVARIAN
CANCER CELLS
(This chapter contains previously published material [266]. See Appendix C)
Abstract
In this chapter, we will describe the association of key oxidant and antioxidant enzymes
as well as specific SNPs in these enzymes with the development of cisplatin resistance in EOC
cells. The foundation of this study is based on previous findings showing an association between
the redox enzymes and EOC in both patients and human cell lines; also the conclusion of the
previous chapter showing an association between key SNPs in the redox enzymes with decreased
overall survival. We hypothesize that the acquisition of resistance to cisplatin in EOC cells is
associated with a pro-oxidant profile, as well as specific SNPs in key oxidant and antioxidant
enzymes. To achieve this, we have utilized two human ovarian cancer cell lines, MDAH-2774
and SKOV-3. For both cell lines, we utilized cisplatin sensitive and cisplatin resistant cells.
DNA was extracted from cells for TaqMan PCR genotyping, RNA was extracted for gene
expression using real-time RT-PCR, protein was utilized for enzymatic activity using ELISA,
and media for NO2−/NO3− levels as a surrogate of iNOS activity using the Griess assay. We have
studied the expression profile of the following genes: CYBA, NOS2, CAT, SOD2, GSR and GPX1.
To analyze the difference in the expression profiles of these genes for sensitive compared to
resistant cells, we have used a Student’s t-test for gene expression, protein activity, and
nitrite/nitrate levels.
Introduction
Oxidative stress is critical for tumorigenesis of EOC and may be linked to cisplatin
resistance. Specifically, an increased expression of pro-oxidant enzymes such as iNOS, MPO,
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NAD(P)H oxidase, as well as an increase in NO as indicated by increased nitrate/nitrite has been
shown in EOC cells [193-195].

Also, EOC cells manifested lower apoptosis, which was

markedly reduced by inhibiting iNOS and MPO, indicating a strong link between apoptosis and
NO/iNOS and MPO pathways in these cells [194]. Reduced caspase-3 activity is indicative of
decreased apoptosis. The platinum-based drugs represent the chemotherapy backbone in the
medical management of EOC. Platinum-resistant ovarian cancer is very common and have been
touted as a major contributor to poor survival in ovarian cancer patients. Although the exact
mechanism of cisplatin resistance in EOC remains elusive, available evidence suggests a role for
oxidants and antioxidants in the development of resistance to chemotherapy. Establishing the
redox profile of EOC cells is a critical step to understand the underpinnings of the potential
relationships between oxidant and antioxidants with diverse key metabolic processes.
In this chapter, we will present our analysis determining whether key oxidant and
antioxidant enzymes are associated with chemoresistance in EOC cells.
Methods
Experimental design
Cell Culture and establishment of cisplatin resistant cell lines. Culture of EOC cell lines
MDAH-2774 and SKOV-3 and their chemoresistant counterparts are described in General
Methods. For measurement of messenger RNA (mRNA), activity and NO2−/NO3− levels, cells
(1.2 x 106) were seeded in 100-mm dishes (Corning, Corning, NY) and allowed to rest for 24
hours followed by media replacement and cell collection 24 hours later.
RNA Isolation and Reverse Transcription of cDNA, for Real-time RT-PCR
Total RNA was extracted from EOC cells using an RNeasy Mini Kit (Qiagen) according
to the protocol provided by the manufacturer. A 20 μL cDNA reaction volume utilizing 1 μg
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RNA was prepared using the Superscript VILO Master Mix (Life Technologies, Carlsbad, CA),
as described by the manufacturer's protocol. Quantitative real-time RT-PCR was performed
using a QuantiTect SYBR Green RT-PCR kit (Qiagen) and the Cepheid 1.2f Detection System
(Cepheid, Sunnyvale, CA). Human oligonucleotide primers were designed with the aid of the
software program, Beacon Designer (Premier Biosoft, Palo Alto, CA). Human oligonucleotide
primers that amplify variable portions of the protein coding regions are established and verified
by our laboratory, as previously described, and are listed in Table 5 [267-270]. The RT-PCR
was performed in a 25 μl total reaction volume including 12.5 μl of 2x QuantiTect SYBR Green
RT-PCR master mix, 5 μl of 10x diluted cDNA template for GSR and 2 μl of undiluted cDNA
template for iNOS, 3 μl of undiluted cDNA template for, p22phox, and CAT; and 1 μL of undiluted
cDNA template for GPX1, p22phox, -actin; and 0.2 μM/L each of target specific primers
designed to amplify each gene. Standards with known concentrations and lengths (base pairs
[bp]) were designed specifically for genes interested using the Beacon Designer software
(Premier Biosoft), allowing for construction of a standard curve using a 10-fold dilution series.
A specific standard for each gene allows for absolute quantification of the gene in a number of
copies, which can then be expressed per μg of RNA. The RT-PCR reaction conditions were
programmed as follows: An initial cycle was performed at 95°C for 900 secs for GSR and 1000
sec for iNOS, and 95 °C for 60 seconds for GPX1, p22phox, and 1800 sec for CAT. This was
followed by 35 cycles of denaturation at 95 °C for 15 secs, annealing for 30 secs 55°C for CAT,
59 °C for GSR, 30 seconds at 59°C for GPX1, 54 °C for p22phox, 72 °C for -actin and, 58°C for
iNOS. A control, containing all the reaction components except for the template, was included in
all experiments. All experiments were performed in triplicate.
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Table 5. Human Oligonucleotide primers.
Accession Number

Gene

Sense (5’-3’)

Antisense (3’-5’)

Amplicon (bp)

NM_001752

CAT

GGTTGAACAGATAGCCTTC

CGGTGAGTGTCAGGATAG

NM_000637

GSR

TCACCAAGTCCCATATAGAAATC

TGTGGCGATCAGGATGTG

116

NM_000581

GPX1

GGACTACACCCAGATGAAC

TTCTCCTGATGCCCAAAC

96

NM_003102

SOD3

GCCTCCATTTGTACCGAAAC

AGGGTCTGGGTGGAAAGG

78

AY288918

NOX4

AACCTTCTTGCTGTATAAC

TGCTTAGACACAATCCTA

77

NM_000101

p22phox

GTACTTTGGTGCCTACTC

GGAGCCCTTCTTCCTCTT

82

NM_001101

β-actin

ATGACTTAGTTGCGTTACAC

AATAAAGCCATGCCAATCTC

79

NM_000625

NOS2

GGCACAGAACTTAAGGATGG

TTGTTAGGAGGTCAAGTAAAGG 145

105

Purification of DNA and the TaqMan SNP Genotyping Assay for SNPs
DNA, from cells, was isolated by the Applied Genomics Technology Center (AGTC,
Detroit, MI) and TaqMan was performed as described in General Methods.
ELISAs
Protein was extracted and concentration determined as described in General Methods.
Unless otherwise stated, all assays were performed utilizing cell lysate according to the
manufacturer’s protocols.
The Catalase Assay Kit (Cayman Chemical, Ann Arbor, MI) utilizes the peroxidatic
function of CAT for determination of enzyme activity and is based on the reaction of the enzyme
with methanol in the presence of an optimal concentration of H2O2. Formaldehyde produced is
measured spectrophotometrically with Purpald as the chromogen, which is detected at 540 nm.
The Glutathione Reductase Assay Kit (Abcam, Cambridge, MA) measures GSR activity
by its ability to reduce GSSG to GSH, which reacts with 5,5-Dithiobis (2-nitrobenzoic acid)
(DTNB) to generate TNB, which can be detected at 405 nm. Absorbance was read once a
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minute for 5 minutes and slope was utilized to calculate GSR activity.
The Glutathione Peroxidase Assay Kit (Abcam, Cambridge) measures GPx activity by
GPx’s ability to reduce Cumene Hydroperoxide while oxidizing GSH to GSSG. GSR reduces the
generated GSSG to GSH with consumption of NADPH. The decrease of NADPH (easily
measured at 340 nm) is proportional to GPx activity. Absorbance was read once a minute for 5
minutes and slope was utilized to calculate GPx activity. The rate of decrease in the absorbance
340 is directly proportional to the GPx activity in the sample.
The nitrate/nitrite colorimetric assay (Cayman Chemical, Ann Arbor, MI) was used to
measure the levels of stable NO by-products, NO2− and NO3−, as an indication of NO production.
Due to the fact that the proportion of NO2− and NO3− is variable and cannot be predicted with
certainty, the sum of both NO by-products is a more accurate indicator of NO production. The
assay was performed utilizing cell culture media. Absorbance was detected at 540 nm and a
standard curve for nitrite was utilized to determine total NO2− and NO3−.
Statistical Analysis
Unpaired t tests were used to compare controls and the resistant cell lines. Statistical
significance was established at P-value less than 0.05 for all analyses.
Results
Cisplatin-resistant SKOV-3 EOC cells have lower p22phox mRNA levels compared to their
chemosensitive counterparts
The p22phox mRNA levels were significantly decreased (from 272.78 ± 18.44 to 104.65 ±
3.61 fg/μg RNA) in cisplatin-resistant MDAH-2774 EOC cells (P<0.05, Figure 3), and in
SKOV-3 EOC cells (from 380.37 ± 38.61 to 70.12 ± 4.25) (P<0.05, Figure 3), as compared to
chemosensitive controls.
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Figure 3. p22phox mRNA levels in sensitive EOC as compared to their resistant counterparts.
RNA was isolated from both sensitive and resistant EOC cell lines (MDAH-2774 and SKOV-3).
Real-time RT-PCR was utilized to measure mRNA. *P<0.05 denotes statistical significance.
Error bars represent standard deviation.
Cisplatin-resistant EOC cells have higher iNOS mRNA levels and NO2−/NO3− levels
The iNOS mRNA levels were significantly increased from 374.18 ± 20.54 to 916.26 ±
96.01 pg/μg RNA in MDAH-2774, and from 366.31 ± 32.67 to 597.34 ± 13.27 pg/μg RNA in
SKOV-3 cisplatin-resistant EOC cells when compared to sensitive counterparts (P < 0.05, Figure
4A) [266].
Correspondingly, NO2−/NO3− levels were significantly increased in MDAH-2774
cisplatin-resistant cells from 12.26 ± 0.04 μM/L to 16.51 ± 0.06 μM/L, and from 8.2 ± 0.0 μM/L
to 13.7 ± 0.2 μM/L in SKOV-3 cisplatin-resistant EOC cells when compared to their sensitive
counterparts (P < 0.05, Figure 4B).
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Figure 4. iNOS mRNA and nitrate/nitrite levels in sensitive EOC as compared to their
resistant counterparts. RNA and protein were isolated from both sensitive and resistant EOC
cell lines (MDAH-2774 and SKOV-3). Real-time RT-PCR was utilized to measure mRNA and
Griess assay measuring nitrate/nitrite levels in protein were utilized. *P<0.05 denotes statistical
significance. Error bars represent standard deviation of the mean.
Chemoresistant EOC cells have an increase in CAT mRNA levels and activity as compared to
their chemosensitive counterparts
Catalase mRNA levels were increased from 1.13 ± 0.18 to 1.96 ± 0.18 fg/μg RNA in
SKOV-3, and from 1.35 ± 0.26 to 2.48 ± 0.09 fg/μg RNA in MDAH-2774 (P<0.05, Figure 5A).
Correspondingly, CAT activity also increased in cisplatin-resistant SKOV-3 (from 6034.66 ±
487.48 to 7884.37 ± 138.66 nmol/min/mL) and MDAH-2774 (from 6156.28 ± 213.32 to 8823.37
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± 257.32 nmol/min/mL) when compared to their sensitive controls (P < 0.05, Figure 5B).
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Figure 5. Catalase mRNA and activity levels in sensitive EOC as compared to their resistant
counterparts. RNA and protein were isolated from both sensitive and resistant EOC cell lines
(MDAH-2774 and SKOV-3). Real-time RT-PCR to measure mRNA and ELISA to measure
protein levels were utilized. *P<0.05 denotes statistical significance. Error bars represent standard
deviation of the mean.
Chemoresistant EOC cells have decreased SOD activity as compared to their chemosensitive
counterparts
The SOD2 mRNA levels decreased (from 9.18 ± 2.25 and 5.27 ± 0.46 to 8.42 ± 1.34 and
5.79 ± 0.30 pg/μg RNA) in MDAH-2774 (P>0.05, Figure 6A) and SKOV-3 respectively (P>0.05,
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Figure 6A), as compared to their chemosensitive controls. The activity of SOD decreased in
cisplatin-resistant MDAH-2774 (from 30,111.06 ± 388.11 to 26,959.88 ± 1011.41 U/ml/mg
protein) and SKOV-3 (from 40,373.40 ± 809.48 to 27,955.97 ± 1600 U/ml/mg protein) when
compared to respective sensitive controls (P < 0.05, Figure 6B).
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Figure 6. SOD2 mRNA and activity levels in sensitive EOC as compared to their resistant
counterparts. RNA and protein were isolated from both sensitive and resistant EOC cell lines
(MDAH-2774 and SKOV-3). Real-time RT-PCR to measure mRNA and ELISA to measure
protein levels were utilized. *P<0.05 denotes statistical significance. Error bars represent
standard deviation of the mean.
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Chemoresistant EOC cells have a decrease in GSR mRNA levels and activity as compared to
their chemosensitive counterparts
There was a significant decrease in the mRNA expression and activity of GSR in both
cisplatin-resistant EOC cell lines when compared to their sensitive counterparts (Figure 7) [266].
The GSR mRNA levels decreased in cisplatin-resistant MDAH-2774 (from 27.7 ± 1.2 to 20.3 ±
0.7 pg/μg RNA) and SKOV-3 (from 30.1 ± 0.6 to 11.6 ± 0.25 pg/μg RNA) when compared to
their chemosensitive controls. (P < 0.05 Figure 7A).
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Figure 7. GSR mRNA and protein activity levels in sensitive EOC as compared to their
resistant counterparts. RNA and protein were isolated from both sensitive and resistant EOC
cell lines (MDAH-2774 and SKOV-3). Real-time RT-PCR to measure mRNA and ELISA to
measure protein levels were utilized. *P<0.05 denotes statistical significance. Error bars
represent standard deviation of the mean.
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Correspondingly, GSR activity also decreased in cisplatin-resistant MDAH-2774 (from
8.5 ± 0.07 to 5.9 ± 0.1 nmol/min/mL) and SKOV-3 (from 10.6 ± 0.1 to 3.9 ± 0.0 nmol/min/mL)
when compared to respective sensitive controls (P < 0.05, Figure 7B).
Chemoresistant EOC cells have an increase in GPX1 mRNA levels and activity as compared to
their chemosensitive counterparts
There was a significant increase in the mRNA expression of GPX1 and activity of GPx in
both cisplatin-resistant EOC cell lines when compared to their sensitive counterparts (Figure 8).
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Figure 8. GPX1 mRNA and activity levels in sensitive EOC as compared to their resistant
counterparts. RNA and protein were isolated from both sensitive and resistant EOC cell lines
(MDAH-2774 and SKOV-3). Real-time RT-PCR to measure mRNA and ELISA to measure
protein levels were utilized. *P<0.05 denotes statistical significance. Error bars represent
standard deviation of the mean.
There was a significant increase in GPX1 mRNA levels (from 141.95 ± 4.13 and 236.95 ± 40.17
pg/μg RNA to 279.22 ± 17.39 and 407.75 ± 20.32 pg/μg RNA) in MDAH-2774 and SKOV-3
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EOC cells, respectively (P<0.05, Figure 8A), as compared to their chemosensitive controls.
Similarly, GPx protein activity increased in cisplatin-resistant MDAH-2774 (from 180.83
± 4.5 to 675.57 ± 5.25 nmol/min/ml/μg protein) and SKOV-3 (from 155.47 ± 9.91 to 750.81 ±
17.71 nmol/min/ml/μg protein) when compared to respective sensitive controls (P < 0.05, Figure
8B).
Chemoresistant EOC cells are associated with mutations in GPX1, SOD2, and CYBA
For both cell lines, our genotyping data did show the presence of the selected SNPs,
except for GPX1, in the cisplatin-sensitive EOC cells. The cisplatin-resistant cells revealed the
presence of point mutations in GPX1, CYBA, and SOD2 genes. The mutations in the SOD2 and
CYBA genes correspond to the selected SNPs in SOD2 and CYBA; and the reversal of the GPX1
SNP. There was a single nucleotide change from T to C in GPX1 and SOD2, and from C to T in
CYBA in the cisplatin-resistant cells compared to their sensitive counterparts. No change has
been observed for CAT, NOS2, or GSR. The data suggest an association between the mutations
and possibly the SNPs, and cisplatin resistance (Table 6).
Table 6. Cisplatin resistance is associated with nucleotide change in CYBA, GPX1 and
SOD2.
Genotype (indicates change to SNP)
Cell Line and Treatment
MDAH-2774 Sensitive
MDAH-2774 Cisplatin
resistant
SKOV-3 Sensitive
SKOV-3 Cisplatin
resistant

CAT
(C→T)
C/C

GPX1
(C→T)
C/T

GSR
(G→T)
G/G

SOD2
(T→C)
T/T

CYBA
(C→T)
T/C

NOS2
(C→T)
C/C

C/C

C/C

G/G

T/C

TT

C/C

C/C

C/T

G/G

T/T

T/C

C/C

C/C

C/C

G/G

T/C

TT

C/C

DNA was isolated from both sensitive and resistant EOC cell lines (MDAH-2774 and SKOV-3). Genotyping was
done utilizing TaqMan probes. For both cell lines, there is a single nucleotide change from T to C in the SOD2, and
GPX1 genes; C to T for CYBA in cisplatin resistant cells compared to their sensitive counterparts. No change has
been observed for CAT, GSR, and iNOS.
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Discussion
In this study, we have shown that both MDAH-2774 and SKOV-3 cells displayed
decreased expression of CAT and GSR with the development of cisplatin resistance (Figure 5A
and B).

Many lines of evidence have linked CAT expression and activity to cancer and

resistance to chemotherapy [178, 271-274]. For example, genetic polymorphisms involving
C262T SNP was associated with increased CAT expression and concomitant reduction of breast
cancer risk [271, 272]. It has also been reported that MCF-7 breast cancer cells overexpressing
CAT not only had impaired proliferation and migration capacities but also, were more sensitive
to anticancer treatments when compared to parent cells [273].

Additionally, others have

demonstrated that both CAT and GPx can inhibit the cisplatin-induced down regulation of Bcl-2,
a powerful anti-apoptosis protein [274].
Glutathione is a powerful antioxidant that plays an important role in preventing ROSinduced damages to vital cellular functions [275-277]. However, it was shown that once cancer
is established, high levels of GSH can be deleterious by preventing the cytotoxic effect of
various chemotherapeutic agents through detoxification and increased activity of efflux pump
[278-280]. Conversely, it has also been reported that low levels of GSH are linked to impaired
immune response and tumor progression [281-283]. The latter is more aligned with our findings,
because low expression of GSR is indicative of low GSH and oxidative stress since GSH will not
be adequately regenerated from its oxidized form (GSSG).

Together, the antioxidant

mechanisms involving both CAT and GSR, when impaired may adversely impact the response to
cisplatin by failing to restore the oxidative balance.
For both cell lines, CYBA was overexpressed in cisplatin-resistant cells supporting the
theory that tumor cells are under intrinsic oxidative stress that may play a role in chemotherapy
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resistance and tumor progression. Indeed, previous report suggests impairment of apoptosisinduced CYBA upregulation conferred resistance to chemotherapy by over-activation of
MEK/ERK pathway in liver tumor cells [284].
Our results suggest that increased expression of iNOS correlates with the development of
resistance to cisplatin. The NO synthase family includes the calcium/calmodulin mediated
isoenzymes eNOS (endothelial) and nNOS (neuronal), in addition to the non-calcium-dependent
iNOS [285].

Earlier studies have shown that NO donors can induce apoptosis at high

concentrations, whereas preventing it at low physiologic levels [286, 287].

Moreover, as

compared to normal cells, cancer cells have significantly increased level of iNOS [288].
Previously, we have reported that increased iNOS activity can lead to S-nitrosylation of
caspase-3 and decreased apoptosis in EOC cells [193]. Also, we have demonstrated that high
levels of iNOS in EOC cells are associated with high levels of vascular endothelial growth factor
(VEGF) production and angiogenesis induction [194]. Additionally, other groups have reported
an inverse relationship between the expression of eNOS/nNOS and iNOS that suggests elevated
expression of iNOS coupled with decreased eNOS/nNOS expression may be associated with
p53-mediated cisplatin resistance in EOC [289]. Conversely, low expression of iNOS in head
and neck squamous cell carcinoma was shown to be associated with resistance to cisplatin/taxolinduced apoptosis mediated through survivin [290]. The physiology of the NO synthase family
is fairly complex and not fully elucidated; however, they appeared to be involved in cisplatin
resistance in many cancers.
Interestingly, the genotyping data revealed point mutations in the SOD2, GPX1, and
CYBA genes for cisplatin resistant cell lines (both MDAH-2774 and SKOV-3) as compared to
their sensitive counterparts. Wild-type SOD2 and GPX1 genes encode for antioxidant proteins,
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which functions are to mitigate oxidative stress; while the CYBA gene encode for oxidants.
The nucleotide change (T to C) observed in the SOD2 gene is consistent with SNP
(rs4880), which results in a decrease in the SOD enzymatic activity due to an amino-acid change
(valine to alanine). As mentioned above, the cisplatin-sensitive cells carry the GPX1 SNP
(rs3448) which was reversed in the cisplatin-resistant cells. No specific amino-acid change or
enzymatic function alterations have been consistently reported; however, in the next chapter we
will provide new insights on the impact of GPX1 genetic editing and cisplatin resistance.
The CYBA gene encodes for the cytochrome b-245 alpha light chain protein (p22phox),
which in humans is involved in O2●– production. It is a component of the NOX complex. The
nucleotide change observed in the CYBA gene is consistent with SNP (rs4673), which has been
reported to a decrease in NOX4 enzymatic activity due to an amino-acid change (tyrosine to
histidine).
The present study suggests a potential relationship between the oxidative state and the
development of cisplatin resistance in ovarian cancer. Additionally, our data suggest a link
between previously reported SNPs in SOD2, NOS2, GPX1 and CYBA genes with cisplatinresistant EOC cells. These findings represent a new direction in our quest to unravel the exact
role of oxidative stress in the establishment of cisplatin resistance in EOC cells and will be the
foundation of the next chapter.
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CHAPTER 5: CAUSAL RELATIONSHIP BETWEEN SOD, CYBA, AND GPX1
SPECIFIC SNPS AND ACQUISITION OF CISPLATIN RESISTANCE IN EPITHELIAL
OVARIAN CANCER CELLS
Abstract
In this chapter, we will discuss whether there is a causal relationship between SOD2,
CYBA, and GPX1 specific SNPs and acquisition of cisplatin resistance in EOC cells. The
rationale of this study is based on the established fact that cisplatin treatment causes DNA
damage, and the observation that specific SNPs in the redox enzymes were found to be
associated with poor survival in ovarian cancer patients. Additionally, our findings from Chapter
4 demonstrated an association between cisplatin resistant cells and point mutations
corresponding to specific SNPs in several redox enzymes. The hypothesis of this study is:
specific SNPs in key oxidant and antioxidant enzymes cause cisplatin resistance. To achieve this,
we utilized the CRISPR/Cas9 system to generate point mutations corresponding to specific SNPs
in selected genes in sensitive MDAH-2774 and SKOV-3 cell lines. Cells were enriched for the
specific point mutation by flow cytometry.

The enriched cells were then cultured with

increasing doses (0.5 to 5 μM) of cisplatin and tested for resistance using the MTT cell viability
assay. IC50 values were derived from equations generated by regression analyses of the MTT
cisplatin dose-response curves. Cisplatin IC50 values from SKOV-3 cells without the point
mutation and those with the point mutation were compared to determine cisplatin resistance.
Introduction
Oxidative stress can result in increased DNA mutations or damage, genome instability,
and cellular proliferation; which have been implicated in the pathogenesis of several
malignancies including ovarian cancer [46, 166, 167, 178, 185-187].

Moreover, there is

evidence of decreased circulating antioxidants in ovarian cancer patients [167].

We have

previously reported that cisplatin resistant EOC cells were associated with an enhanced oxidative
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state, indicating that oxidative stress may play a role in maintaining the oncogenic phenotype of
EOC cells [291]. In an attempt to determine the mechanisms underlying this observation, we
selected and tested for the presence of specific functional SNPs known to be associated with
cancer. In the parent cell lines, only GPX1 revealed the presence of the SNP. Surprisingly, we
found point mutations in CYBA, SOD2 and GPX1 (reversal of the SNP) that were identical to the
selected SNPs, indicating that exposure to cisplatin or other factors may have been responsible
for the occurrence of de novo mutations. Indeed, pharmacokinetically, cisplatin avidly binds and
damages DNA, hence creating the possibility of translesion synthesis, whereby DNA synthesis
is not blocked but proceeds beyond cisplatin due to specific classes of polymerases [88, 96].
Here, we sought to test whether there is a causal relationship between the point mutations
corresponding to known SNPs in key redox genes and cisplatin resistance in SKOV-3 and
MDAH-2774 EOC human cell lines.
Methods
Experimental design
Culture of EOC cell lines MDAH-2774 and SKOV-3 and their chemoresistant
counterparts are described in General Methods.
Following design of a genomic DNA target sequence for SOD, CYBA and GPX1, the
GeneArt CRISPR kit (Life Technologies, Carlsbad, CA) was used to generate double stranded
oligonucleotides (ds oligo), per the manufacturer’s protocol. The ds oligo was cloned via a
ligation reaction into a CRISPR vector. Cloning of the CRISPR vector was performed in
chemically competent E. coli included in the kit. These cells are ideal for high-efficiency
cloning and plasmid propagation, and allow stable replication of high-copy number plasmids.
Transformed E. coli were transferred onto Luria broth (LB) agar plates containing 100 μg/ml
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ampicillin and grown overnight resulting in ampicillin-resistant colony formation. A single
colony was grown in LB medium containing 100 μg/ml ampicillin overnight and subsequently
purified using the HI Pure Plasmid Mini Prep Kit (Life Technologies), per the manufacturer’s
protocol. For transfection of the plasmid into our EOC cells, cells were plated (400,000) in a 6well dish and allowed to grow overnight. Cells were transfected once they reached ~80%
confluency. 250 μl of Opti-MeM (Life Technologies) was used for transfection and included the
specific concentration of the CRISPR vector in a 1:3 ratio of the TransIT-X2 transfection reagent
(Mirus Biologicals, Madison, WI). The cells were incubated for 24 hours and the presence of
fluorescence served as confirmation of transfection of the cells as the CRISPR system contains
an orange fluorescence protein reporter.
The CRISPR transfected cells were enriched using Fluorescence-activated cell sorting
(FACS) (Figure 9).

Figure 9. Fluorescenceactivated cell sorting plots
(FACS). Cells expressing the
orange fluorescent protein
(OFP) were sorted as
depicted by the cells located
inside of the boxes labeled
“OFP+”.

52
Cell sorting was performed at the Wayne State University Microscopy, Imaging, and
Cytometry (MICR) Resources Core Facility. Cells expressing the orange fluorescent protein
(OFP) were sorted on a Sony SY3200 cell sorter equipped with 355 nm, 405 nm, 488 nm, 561
nm, and 642 nm lasers (Sony Biotechnology, San Jose, CA). The SKOV-3 EOC cell lines with
the SOD point mutation were further analyzed for activity using an ELISA, as described in
General Methods. Additionally, cell viability will be determined utilizing the Vybrant MTT
Cytotoxicity Assay (Invitrogen) following treatment with increasing doses of cisplatin (0.5 to 5
μM) for 72 hours.
Statistical analysis
For each MTT viability assay, a cisplatin dose-response curve was generated in the form
of a scatter plot with a linear regression line. Then, the predicted cisplatin IC50 value was
determined using the regression equation. Comparisons between cell lines were done using the
predicted cisplatin IC50 values, with lower values indicate cisplatin sensitivity and higher values
cisplatin resistance. Baseline cisplatin IC50 values were previously established for both MDAH2774 and SKOV-3 cell lines and served as controls, as described in Chapter 2. P-values were
based on the predicted minimum and maximum 95% CIs. Again, to analyze the difference in
protein activity of SOD between controls, cisplatin resistant and point mutation-induced EOC
cell lines, unpaired t-tests were used. For all analyses, P-value less than 0.05 is considered
statistically significant.
Results
Induction of the point mutation corresponding to a known function SNP in SOD2 resulted in
lower SOD activity in both MDAH-2774 and SKOV-3 EOC cell lines.
We have successfully transfected both MDAH-2274 and SKOV-3 chemo-naïve cells with
the CRISPR/Cas9 system and demonstrated a significant decrease in activity of SOD in both the

53
MDAH-2774 and SKOV-3 EOC cell lines following the induction of the point mutation
corresponding to a specific SNP (Figure 10).
12000
SOD (U/ml/mg protein)

MDAH-2774
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Figure 10. SOD activity levels for
the point mutation-induced EOC
cells as compared to untreated
controls. ELISA results show a
significant reduction of the SOD
activity in the point mutation-induced
EOC cells as compared to untreated
counterparts.
*P<0.05
denotes
statistical significance. Error bars
represent standard deviation.
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Both MDAH-2774 and SKOV-3 cisplatin resistant EOC cell lines demonstrated a higher
cisplatin IC50 compared to their sensitive counterparts
The cisplatin IC50 for MDAH-2774 cisplatin resistant cells was 6.34 (95% CI [6.196.49]) compared to 1.70 (95% CI [1.66-1.74]) for their cisplatin sensitive counterparts (P<0.05),
a 2.73-fold change (Figure 11, Table 7). Similarly, the cisplatin IC50 for SKOV-3 cisplatin
resistant cells was 3.31 (95% CI [3.27-3.35]) compared to 1.87 (95% CI [1.83-1.91]) for their
cisplatin sensitive counterparts (P<0.05), a 0.77-fold change (Figure 12, Table 7).
Figure 11. Cell viability
assay for MDAH-2774
human EOC cells. The
red
curve
depicts
resistant
cells
as
compared to the blue
curve, which depicts
sensitive cells. IC50: the
dose of cisplatin that kills
50% of cells.
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Table 7. Predicted cisplatin IC50 for SKOV-3 EOC cells.
Predicted
IC50
1.87
3.31

Cell Line
SKOV-3 sensitive
SKOV-3 resistant

1.83
3.27

95% CI
max
1.91
3.35

Foldchange
0.00
0.77

2.77
3.58
1.70

2.80
3.62
1.77

0.49
0.92
-0.08

95% CI min

P-value
<0.05
<0.05

Point Mutation-Induced
Sensitive SKOV-3 EOC Cells

2.79
3.60
1.73

MnSOD
GPX1
CYBA

<0.05
<0.05
<0.05

100%

Viable cells

75%

50%

25%
SKOV-3 sensitive
SKOV-3 resistant
0%
0

0.5

1

1.5
2
2.5
Cisplatin concentration (μM)

3

3.5

4

Figure 12. Cell viability assay for SKOV-3 human EOC cells. The blue curve depicts
resistant cells as compared to the red curve, which depicts sensitive cells. IC50: the dose of
cisplatin that kills 50% of cells.
SKOV-3 cisplatin sensitive cells demonstrated a shift in the cisplatin IC50 after introduction of
point mutations
The SKOV-3 EOC cells with the SOD2 point mutation (Table 6) revealed a cisplatin IC50
of 2.79 (95% CI [2.77-2.80]) compared to 1.87 (95% CI [1.83-1.91]) for their cisplatin sensitive
counterparts (P<0.05), indicating that the introduction of the point mutation corresponding to the
SOD2 SNP (rs4880) rendered the cells resistant to cisplatin by a 0.49-fold change (Figure 13,
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Table 7). Similarly, the SKOV-3 EOC cells with the GPX1 point mutation revealed a cisplatin
IC50 of 3.60 (95% CI [3.58-3.62]) compared to 1.87 (95% CI [1.83-1.91]) for their cisplatin
sensitive counterparts (P<0.05), indicating that the introduction of the mutation corresponding to
the reversal of GPX1 SNP (rs3448) rendered the cells resistant to cisplatin by a 0.92-fold change
(Figure 14, Table 7). Interestingly, the SKOV-3 EOC cells with the CYBA point mutation
revealed a cisplatin IC50 of 1.73 (95% CI [1.70-1.77]) compared to 1.87 (95% CI [1.83-1.91]) for
their cisplatin sensitive counterparts (P<0.05), indicating that the introduction of the point
mutation that corresponds to CYBA SNP (rs4673), sensitized the cells to cisplatin, by a -0.08-fold
change (Figure 15, Table 7).
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Figure 13. Cell viability assay for SKOV-3 human EOC cells harboring the SOD point
mutations corresponding to SNP (rs4880). IC50: the dose of cisplatin that kills 50% of cells.
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Figure 14. Cell viability assay for SKOV-3 human EOC cells harboring the GPX1 point
mutation corresponding to the reversal of SNP (rs3448). IC50: the dose of cisplatin that kills
50% of cells.
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Figure 15. MTT cell viability assay for SKOV-3 human EOC cells harboring the CYBA
point mutation corresponding to SNP (rs4673). IC50: the dose of cisplatin that kills 50% of
cells.
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Discussion
In this study, we have used the CRISPR/Cas9 system to successfully generate point
mutations in SKOV-3 chemosensitive EOC cells. Subsequently, we have established cisplatin
IC50 values for SKOV-3 sensitive, resistant and mutation-induced cell lines. By comparing the
IC50 values, we determined that the cells with point mutations for GPX1 and SOD have become
resistant to cisplatin. Interestingly, we found that the creation of the point mutation in the CYBA
gene increases their sensitivity to cisplatin. As outlined in the previous chapter, the point
mutations which correspond to specific SNPs in, SOD2 and CYBA were originally observed in
both SKOV-3 and MDAH-2774 cisplatin-resistant cell lines. For both cell lines, the GPX1 SNP
was observed only in the cisplatin-sensitive cells.
The SKOV-3 EOC cells were found to be highly resistant to cisplatin when the specific
GPX1 mutation is present. Moreover, the magnitude the cisplatin resistance, as indicated by the
IC50 value, was greater in the SKOV-3 cells with the CRISPR-induced GPX1 point mutation,
than the resistant controls. This indicates that GPX1 is a major contributor of cisplatin resistance
and is consistent with the literature. The GPX1 gene located at 3p21.31 encodes for GPx, which
is one of the most important antioxidants in humans and functions in the detoxification of
hydrogen peroxide [292-294].

Variations in GPX1 (rs3448) were associated with overall

prostate cancer risk with an odds ratio of 0.62 for the mutant (TT) versus the wild-type (CC)
(95% confidence interval, 0.44-0.88); as well as breast cancer risk [295, 296]. Decreased levels
or activity of GPx is associated with colorectal cancer in humans; however in esophageal cancer,
its expression is thought to drive aggressive growth and metastasis, partly through cisplatin
resistance [292, 297].

GPX1 variants heavily influenced cellular biology, suggesting that

different GPX1 variants affect cancer risk differently [298].
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Associations between high levels of GSH, glutathione transferase and chemoresistance in
patients with ovarian cancer have been widely reported [297, 299-302]. These observations are
consistent with the known role of the MDR membranous proteins pumps, as they could be
modulated by the GSH/GSSG system.

These proteins, when activated, export several

chemotherapeutic drugs, including cisplatin, outside of the cells thereby decreasing their
effective concentrations. In one study, it was suggested that the GSH system may be involved in
the mechanism of chemoresistance in ovarian cancer, as explained by the upregulation of GSH
and MRP expression modulated by gamma-GCS [303].
The SOD2 point mutation was also found to be associated with cisplatin resistance.
Intriguingly, the IC50 exhibited by the sensitive SKOV-3 EOC cells with the SOD2 mutation was
higher than the SKOV-3 control EOC cells but lower than the SKOV-3 cisplatin resistant EOC
cells, where the mutation was originally observed. This discrepancy suggests that, additional
factors may contribute to the cisplatin resistance in these cells. We demonstrated that the SOD2
mutated cells manifest a decrease in activity consistent with what has been reported for the SNP
(rs4880).
Evidence in several cancers suggests that antioxidants such as SOD may decrease cell
killing, hence promoting cisplatin resistance [304-307]. Indeed, salinomycin, an antibacterial
drug with anticancer activity, induces cell death in cisplatin-resistant colon adenocarcinoma
(SW620) cells via down-regulations of SOD and GPx activities. These observations were
associated with a decrease of the Bcl-2/Bax ratio, indicating a tilt towards apoptosis [305]. In
cisplatin-resistant urothelial carcinoma (NTUB1) cells, cisplatin-induced overexpression of the
CCAAT/enhancer binding protein delta (CEBPD, C/EBPdelta, NF-IL6beta) was found to be
associated with decrease of ROS through the upregulation of SOD1 via direct promoter
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transactivation. This has led to decrease ROS-triggered apoptosis, hence cisplatin resistance
[306]. Similar observation was found in other systems and implicated other antioxidants such as
CAT and GPx [306, 307].
Conversely, in gastric cancer, antioxidants were found to be beneficial. Ginkgo biloba
extract (EGb) 761 was reported to possess antitumor activity that may be related to the KSR1mediated ERK signaling pathway. Specifically, EGb 761 reduced the expression of various
cisplatin and etoposide-induced mitogenic genes; the malondialdehyde (MDA) content; and
elevated the activities of SOD and GPx. EGb 761 enhanced the chemotherapy sensitivity and
reversed the chemoresistance through suppression of the KSR1-mediated ERK1/2 pathway in
gastric cancer cells, and the underlying mechanism may be related to its antioxidant activity
[304].
The mutant TT genotype of the CYBA gene translates into a decrease in activity of the
protein, thereby decrease the generation of O2●– and limiting oxidative stress. CYBA or CYBB,
encodes for p22phox or NOX2 respectively and mutations in both lead to chromic granulomatous
disease (CGD) [308]. Contrary to CYBB, CYBA is susceptible to a relatively high number of
SNPs that could influence the level of ROS generation.

These SNPs are associated with

hypertension, coronary artery disease, coronary heart disease, and, cerebral ischemic diseases
[309-311]. Stable overexpression of p22phox increases cisplatin resistance in oral squamous cell
carcinoma, which was reversed by the knockdown of the gene.
preventing nuclear localization of cisplatin [312].

The mechanism involves

This observation in consistent with our

findings with the presence of the mutant TT genotype, indicating that lower expression or
activity of p22phox confers sensitivity to cisplatin. Conversely, CYBA was among five genes
that were found to be lost through methylation, and were associated with tumor progression and
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metastasis in malignant melanoma [313]. Although one of the genes was strongly associated
with cisplatin resistance, CYBA was not [313].
We strongly believe that, thus far, our data does not fully explain the link between low
CYBA expression and cisplatin resistance. However, if validated, it would be worthwhile to
investigate the underlying mechanisms; the resolution of which may lead to the discovery of new
cisplatin sensitizing drugs with significant impact on improved survival outcome. We attempted
to establish causality between specific SNPs in CYBA, SOD2, and GPX1 and the acquisition of
cisplatin resistance in SKOV-3 EOC cells. It would be important to confirm these findings in
MDAH-2774 cell line. Moreover, reversing the mutation in both SKOV-3 and MDAH-2774
EOC cell lines, and demonstrating cisplatin sensitivity will further test the hypothesis that
specific SNPs in key oxidant and antioxidant enzymes cause cisplatin resistance.
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CHAPTER 6: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS
The main objective of the present work is to determine whether oxidative stress is
responsible for the acquisition of cisplatin resistance in EOC.

As stated above, previous

evidence from both our laboratory and others suggests that oxidative stress not only plays an
important role in tumorigenesis, but also cancer progression and aggressiveness. We have
demonstrated that: 1) the overall survival rate is shorter in ovarian cancer patients patients that
carry a specific SNP in the CAT gene, 2) cisplatin resistant human EOC cell lines manifest a prooxidant state, 3) point mutations corresponding to known SNPs in SOD, and CYBA genes are
present in cisplatin resistant cells, while absent in their sensitive counterparts, suggesting a
strong association between cisplatin resistance and those SNPs, 4) for both cell lines, the
cisplatin-sensitive parent cells carry a specific GPX1 SNP, reversal of which, makes the cells
resistant to cisplatin, and 5) we have successfully generated point mutations in the sensitive EOC
cells that correspond to the SNP genotype in our chemoresistant EOC cells using CRISPR/Cas9
system. Additionally, we have established cisplatin IC50 values for sensitive, resistant and
mutation-induced cell lines, as well as demonstrated the acquisition of cisplatin resistance with
GPX1 and SOD mutations. Lastly, we found that the presence of the CYBA mutation in the
sensitive SKOV-3 cells renders them more sensitive to cisplatin as indicated by a lower IC50.
Epithelial ovarian cancer remains a deadly disease. In fact, it is the deadliest of all
gynecologic cancers with an estimated 22,280 new cases and 14,240 deaths expected in 2016 in
the US alone [28]. Although a relatively rare disease, the mortality rate of EOC remains
relatively unchanged for the last four decades. Among the keys factors driving these statistics
are: the lack of universal screening stools for the general population making prevention and early
detection a real challenge; and the limited opportunities for cure due the intrinsic limitations of
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surgery and the development of resistance to standard chemotherapy. Therefore, it is of public
health interest to continue to support both basic science and translational research in this field.
Future studies testing the impact of scavenging oxidants and/or adding antioxidants to
chemotherapy-resistant EOC cell lines are needed. Indeed, we are designing experiments using
patient-derived cisplatin-resistant EOC cells treated with CAT-SKL, a novel drug previously
reported to increase mitochondrial CAT activity [314, 315]. Similarly, we are testing whether
treating the EOC cells with SOD, GPx and GSR purified proteins as well as their inhibitors
influences their response to cisplatin exposure. Preliminary results suggest that antioxidants may
behave differently in sensitive and resistant EOC cells. Understanding the precise mechanism by
which the EOC redox profile relates to the development of cisplatin resistance will have the
potential to significantly impact survival of ovarian cancer patients.
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Epithelial ovarian cancer is the deadliest of all gynecologic cancers with an estimated
22,280 new cases and 14,240 deaths expected in 2016 in the US alone. This high mortality rate
can be partially attributed to a lack of universal screening and the development of resistance to
the recommended chemotherapeutics. Typically, the treatment of ovarian cancer requires both
cytoreductive surgery (CRS) and platinum/taxane combination chemotherapy. Initially, 50–80%
of patients with advanced disease will achieve complete clinical response. Unfortunately, most
will relapse within 18 months with chemoresistant disease. Thus, understanding the mechanisms
of platinum resistance is critical in order to improve the care of ovarian cancer patients. Several
theories to explain cisplatin resistance have been proposed but failed to translate into clinical
practice. Typically drug resistance mechanisms are multifactorial but can be broadly categorized
as follows: 1) pharmacokinetic, resulting in inadequate intratumor cisplatin concentration, 2)
tumor micro-environment, involving membrane transporters by reducing cisplatin uptake or
increasing efflux, 3) increased inactivation and sequestration of cisplatin, 4) activation of DNA
repair and antiapoptotic mechanisms, 5) decreased autophagy and, 6) cancer-cell specific
mechanisms such as: acquired somatic mutations and epigenetic changes and persistence of slow
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growing cancer stem cells that maintain the cancer phenotype.
We have recently characterized EOC tissues and cells to manifest a persistent pro-oxidant
state with the upregulation of several key oxidant enzymes including: myeloperoxidase (MPO),
inducible nitric oxide synthase (iNOS), and nicotinamide adenine dinucleotide phosphate
(NAD(P)H) oxidase with concurrent decrease in apoptosis compared to normal human ovarian
tissues and cells. More importantly, shutting down the expression of one or more of these key
oxidant enzymes reduced the pro-oxidant state, and significantly induced apoptosis. Singlenucleotide polymorphisms (SNPs) are point mutations that are selectively maintained in
populations and are distributed throughout the human genome at an estimated overall frequency
of at least one in every 1000 base pairs. Several SNPs in key oxidants and antioxidants enzymes
have been associated with various cancers including ovarian. Therefore, we are proposing the
following hypothesis: cisplatin treatment induces mutations in key oxidant and antioxidant
enzymes resulting in further enhancement of oxidative stress and the acquisition of resistance in
EOC cells. To test this hypothesis, we are proposing then following specific aims:
Specific Aim 1: To determine the association of specific single nucleotide polymorphisms
(SNPs) in key oxidant and antioxidant enzymes with EOC risk and survival in patients.
The rationale of this aim is based on the fact that oxidative stress is strongly associated
with several cancers, including ovarian. Known specific SNPs in oxidant and antioxidant genes
may alter their expression profile and enzymatic functions. These SNPs have been reported to be
associated not only with cancer risks, but also patient response to treatment and survival. The
hypothesis of this aim is that specific SNPs in key oxidant and antioxidant enzymes are
associated with overall patient survival. To achieve this aim, we will perform a case-control
study using stored blood samples of research participants from the Karmanos Cancer Center.
Individuals (n=143) recruited were divided into controls (n=94),) and ovarian cancer cases
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(n=49). Samples will undergo DNA extraction followed by TaqMan® SNP genotype analysis
for rs4880 manganese superoxide dismutase (MnSOD), rs4673 (NAD(P)H oxidase (CYBA),
rs3448 glutathione peroxidase (GPX1), rs2297518 inducible nitric oxide synthase (iNOS),
rs1002149 glutathione reductase (GSR), and rs1001179 catalase (CAT). We will perform a
multivariate analysis for identification of confounding variables and potential predictors of risk.
Additionally, to study the impact of the SNPs on overall survival, Cox regression and KaplanMeier survival analyses will be used.
Specific Aim 2: To determine the association of key oxidant and antioxidant enzymes as
well as specific SNPs in these enzymes with the development of cisplatin resistance in EOC
cells.
The rationale of this aim is based on previous findings showing an association between
the altered redox enzymes and EOC, in both patients and human cell lines. The hypothesis of
this aim is that the acquisition of resistance to cisplatin in EOC cells is associated with enhanced
pro-oxidant profile, as well as specific SNPs in key oxidant and antioxidant enzymes. To achieve
this aim, we will utilize two human EOC cell lines, MDAH-2774 and SKOV-3 and their
cisplatin resistant counterparts. We will perform TaqMan PCR genotyping, real-time RT-PCR,
ELISA, and Griess assay to study the expression profile of the following genes: CYBA/NOX4,
iNOS, CAT, SOD3, GSR and GPX1. To analyze the difference in the expression profiles of these
genes for sensitive compared to resistant cells, we will use a Student’s t-test.
Specific Aim 3: To determine whether specific SNP(s) in key oxidant and antioxidant
enzymes cause the acquisition of cisplatin resistance in EOC cells.
The rationale of this aim is based on the established fact that cisplatin treatment causes
DNA damage, and the observation that specific SNPs in the redox enzymes were found to be
associated with poor survival in patients. The hypothesis of this aim is: specific SNPs in key
oxidant and antioxidant enzymes cause cisplatin resistance. To achieve this aim, we will utilize
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the CRISPR/Cas9 system to generate point mutations in sensitive EOC cells corresponding to the
SNP genotype of the chemoresistant MDAH-2774 and SKOV-3 EOC cells. The cells will then
be tested for cisplatin resistance using the MTT viability assay using the IC50 method. Results
will be analyzed with regression analysis and student t-tests.

114
AUTOBIOGRAPHICAL STATEMENT
Jimmy Belotte, MD, F.A.C.O.G.
EDUCATION
09/2012-present

Ph.D. – Reproductive Sciences Concentration, Wayne State University, School
of Medicine, Department of Physiology, Detroit, MI
10/1996-9/2003
M.D. - Universite Notre Dame d’Haiti, Faculte de Medecine et des Sciences de la
Sante, Port-Au-Prince, Haiti.
POSTGRADUATE TRAINING
01/2010-062011
Wayne State University School of Medicine, Detroit, MI Ob/Gyn, PGY III/IV
07/2007-12/2009
Nassau University Medical Center, Ob/Gyn/, East Meadow, NY, / Resident,
PGY I/II/III
HONORS/AWARDS
05/2014
Wayne State University, School of Medicine, Ob/Gyn., Detroit, MI, C.S. Mott
Center Scientific Retreat, Best poster in Clinical Research Category.
09/2013
Wayne State University, School of Medicine, Detroit, MI, Office of Vice
president for Research, Travel award
09/2011-present
Wayne State University, School of Medicine, Ob/Gyn, Detroit, MI, Women's
Reproductive Health Research (WRHR) K-12 NIG grant
01/2011
Wayne State University, School of Medicine, Ob/Gyn, Detroit, MI, MFM Award,
Wayne State University
SELECTED PUBLICATIONS
Original Work
1. Nusrat O, Belotte J, Fletcher NM, Memaj I, Saed MG, Diamond MP, Saed GM. The Role of
Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer. Reprod Sci. 2016
Apr 26. PMID: 27122375.
2. Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, Saed GM. A Single
Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival. PLoS One.
2015 Aug 24;10(8): e0135739. PMID: 26301412.
3. Belotte J, Fletcher NM, Alexis M, Morris RT, Munkarah AR, Diamond MP, Saed GM. Sox2
gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Reprod Sci. 2015 Jan;22(1):38-46. PMID: 25038052.
4. Belotte J, Fletcher NM, Awonuga AO, Alexis M, Abu-Soud HM, Saed MG, Diamond MP, Saed
GM. The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian
cancer. Reprod Sci. 2014 Apr;21(4):503-8. PMID: 24077440.
5. Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, Diamond MP, Abu-Soud
HM, Saed GM. Myeloperoxidase and free iron levels: potential biomarkers for early detection
and prognosis of ovarian cancer. Cancer Biomark. 2012;10(6):267-75. PMID: 22820082.
Case Reports
1. Belotte J, Belotte J, Alexis M, Awonuga AO, Aguin TJ. Successful laparoscopic management of
ruptured tubal pregnancy with an ipsilateral ectopic pelvic kidney. Case Rep Obstet Gynecol. 2014;
2014:682737. PMID: 25136465.
2. Belotte J, Awonuga AO, Bolinjkar R, Alexis M, Tabassum F, Deppe G. Platinum-based
combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the
vulva. Obstet Gynecol. 2012 Aug;120(2 Pt2):458-60. PMID: 22825265.
3. Belotte J, Shavell VI, Awonuga AO, Diamond MP, Berman JM, Yancy AF. Small bowel
obstruction subsequent to Essure microinsert sterilization: a case report. Fertil Steril. 2011
Jul;96(1): e4-6. PMID: 21565339.

